Fidelity® Variable Insurance Products:

VIP Contrafund^{s™} Portfolio

Semi-Annual Report June 30, 2023





Contents

Investment Summary	3
Schedule of Investments	4
Financial Statements	12
Notes to Financial Statements	19
Shareholder Expense Example	25
Board Approval of Investment Advisory Contracts	26
Liquidity Risk Management Program	27

To view a fund's proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission's (SEC) web site at http://www.sec.gov.

You may also call 1-877-208-0098 to request a free copy of the proxy voting guidelines.

Fidelity® Variable Insurance Products are separate account options which are purchased through a variable insurance contract.

Standard & Poor's, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation.

Other third-party marks appearing herein are the property of their respective owners.

All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2023 FMR LLC. All rights reserved.

This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund. This report is not authorized for distribution to prospective investors in the Fund unless preceded or accompanied by an effective prospectus.

A fund files its complete schedule of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-PORT. Forms N-PORT are available on the SEC's web site at http://www.sec.gov. A fund's Forms N-PORT may be reviewed and copied at the SEC's Public Reference Room in Washington, DC. Information regarding the operation of the SEC's Public Reference Room may be obtained by calling 1-800-SEC-0330.

For a complete list of a fund's portfolio holdings, view the most recent holdings listing, semiannual report, or annual report on Fidelity's web site at http://www.fidelity.com, http://www.finstitutional.fidelity.com, or http://www.401k.com, as applicable.

NOT FDIC INSURED • MAY LOSE VALUE • NO BANK GUARANTEE

Neither the Fund nor Fidelity Distributors Corporation is a bank.

Investment Summary June 30, 2023 (Unaudited)

Top Holdings (% of Fund's net assets)

Microsoft Corp.	8.8
Apple, Inc.	6.1
Alphabet, Inc. Class C	5.9
Meta Platforms, Inc. Class A	5.8
Berkshire Hathaway, Inc. Class B	4.2
NVIDIA Corp.	4.0
UnitedHealth Group, Inc.	3.7
Amazon.com, Inc.	3.3
Eli Lilly & Co.	3.0
Costco Wholesale Corp.	1.6
	46.4

Market Sectors (% of Fund's net assets)

Information Technology	30.7
Health Care	15.7
Communication Services	14.1
Financials	12.3
Consumer Discretionary	8.7
Industrials	5.3
Energy	4.2
Consumer Staples	3.6
Materials	2.1
Utilities	0.6
Real Estate	0.0

Asset Allocation (% of Fund's net assets)

Stocks - 97.3

Short-Term Investments and Net Other Assets (Liabilities) - 2.7



Schedule of Investments June 30, 2023 (Unaudited)

Showing Percentage of Net Assets

Common Stocks – 96.8%	Shares	Value (\$)
COMMUNICATION SERVICES - 14.0%		
Entertainment - 1.9%	490 100	41 001 100
Activision Blizzard, Inc. Liberty Media Corp. Liberty Formula One Series C (a)	489,100 403,827	41,231,130 30,400,097
Netflix, Inc. (a)	617,099	271,825,939
The Walt Disney Co. (a)	18,858	1,683,642
Universal Music Group NV	745,561	16,555,868
·		361,696,676
Interactive Media & Services - 11.8%		
Alphabet, Inc.:		
Class A (a)	200	23,940
Class C (a)	9,508,682	1,150,265,262
Bumble, Inc. (a) Epic Games, Inc. (a)(b)(c)	194,500 18,849	3,263,710 13,268,942
Meta Platforms, Inc. Class A (a)	3,912,122	1,122,700,772
	5,712,122	2,289,522,626
Media - 0.3%		
Comcast Corp. Class A	1,277,300	53,071,815
Wireless Telecommunication Services - 0.0%		
T-Mobile U.S., Inc. (a)	82,000	11,389,800
TOTAL COMMUNICATION SERVICES		2,715,680,917
CONSUMER DISCRETIONARY - 8.7%		
Automobiles - 0.2%		
BYD Co. Ltd. (H Shares)	141,000	4,521,117
General Motors Co.	48,000	1,850,880
Harley-Davidson, Inc.	41,500	1,461,215
Hyundai Motor Co. Ltd.	128,600	20,229,280
Rad Power Bikes, Inc. (a)(b)(c)	401,674	895,733
Rivian Automotive, Inc. (a)	11,312	188,458
Tesla, Inc. (a)	13,600	3,560,072
Toyota Motor Corp.	841,200	<u>13,519,841</u> 46,226,596
Broadline Retail - 3.5%		40,220,370
Amazon.com, Inc. (a)	4,914,640	640,672,470
Coupang, Inc. Class A (a)	999,395	17,389,473
Dollarama, Inc.	66,000	4,469,915
MercadoLibre, Inc. (a)	6,300	7,462,980
		669,994,838
Distributors - 0.1% Genuine Parts Co.	05 000	1/ 07/ 050
Genuine Parts Co. Hotels, Restaurants & Leisure - 1.2%	95,000	16,076,850
Airbnb, Inc. Class A (a)	399,012	51,137,378
Booking Holdings, Inc. (a)	3,200	8,641,056
Cava Group, Inc.	42,900	1,756,755
Chipotle Mexican Grill, Inc. (a)	8,585	18,363,315
Churchill Downs, Inc.	19,600	2,727,732
Deliveroo PLC Class A (a) (d)	347,500	505,317
Evolution AB (d)	12,500	1,582,934
Hilton Worldwide Holdings, Inc.	219,600	31,962,780
Hyatt Hotels Corp. Class A	12,900	1,478,082
Las Vegas Sands Corp. (a)	35,500	2,059,000
Marriott International, Inc. Class A	5,900	1,083,771
McDonald's Corp.	344,000	102,653,040
Restaurant Brands International, Inc.	57,600	4,465,821

Common Stocks – continued		
common slocks - commoed	Shares	Value (\$)
CONSUMER DISCRETIONARY — continued		
Hatala Dastanuanta O Laisuna continuad		
Hotels, Restaurants & Leisure – continued Starbucks Corp.	11,400	1 120 284
Sidibucks colp.	11,400	<u>1,129,284</u> 229,546,265
Household Durables - 0.4%		227,540,205
D.R. Horton, Inc.	54,700	6,656,443
Lennar Corp. Class A	237,778	29,795,961
NVR, Inc. (a)	3,145	19,972,700
PulteGroup, Inc.	255,000	19,808,400
		76,233,504
Leisure Products - 0.0%		
Bandai Namco Holdings, Inc.	34,800	805,875
Specialty Retail - 3.1%		
Academy Sports & Outdoors, Inc.	445,053	24,055,115
AutoZone, Inc. (a)	37,018	92,299,200
Dick's Sporting Goods, Inc.	296,129	39,145,293
Fanatics, Inc. Class A (a) (b) (c)	232,280	17,839,104
Fast Retailing Co. Ltd.	14,000	3,590,647
Lowe's Companies, Inc.	305,300	68,906,210
O'Reilly Automotive, Inc. (a)	124,700	119,125,910
The Home Depot, Inc.	473,360	147,044,550
TJX Companies, Inc.	193,954	16,445,360
Tractor Supply Co. (e)	21,500	4,753,650
Ulta Beauty, Inc. (a)	64,295	30,256,906
Wayfair LLC Class A (a) Williams Senama Inc	12,900	838,629
Williams-Sonoma, Inc.	238,304	29,821,363
Textiles, Apparel & Luxury Goods - 0.2%		594,121,937
Deckers Outdoor Corp. (a)	13,559	7,154,542
Dr. Martens Ltd.	89,576	139,130
NIKE, Inc. Class B	149,830	16,536,737
On Holding AG (a)	521,935	17,223,855
Ralph Lauren Corp. (e)	9,300	1,146,690
Tapestry, Inc.	75,000	3,210,000
	,	45,410,954
TOTAL CONSUMER DISCRETIONARY		1,678,416,819
CONSUMER STAPLES - 3.6%		
Beverages - 0.6%		
Anheuser-Busch InBev SA NV	89,400	5,066,964
Constellation Brands, Inc. Class A (sub. vtg.)	14,300	3,519,659
Diageo PLC	290,036	12,468,939
PepsiCo, Inc.	261,670	48,466,517
The Coca-Cola Co.	780,500	47,001,710
	,,	116,523,789
Consumer Staples Distribution & Retail - 1.9%		
Alimentation Couche-Tard, Inc. Class A (multi-vtg.)	169,400	8,686,425
Casey's General Stores, Inc.	30,692	7,485,165
Costco Wholesale Corp.	557,001	299,878,198
Dollar General Corp.	247,400	42,003,572
Walmart, Inc.	48,200	7,576,076
		365,629,436
Food Products - 0.3%		
Lamb Weston Holdings, Inc.	332,200	38,186,390

Common Stocks – continued	c'	
	Shares	Value (\$)
CONSUMER STAPLES — continued		
Food Products — continued		
Mondelez International, Inc.	237,900	17,352,420
·	· =	55,538,810
Household Products - 0.6%		
Procter & Gamble Co.	755,000	114,563,70
Personal Care Products - 0.2%		
Estee Lauder Companies, Inc. Class A	173,000	33,973,74
Kenvue, Inc.	160,700	4,245,69
L'Oreal SA (a)	19,100	8,909,69
L'Oreal SA	1,400	653,06
Olaplex Holdings, Inc. (a)	513,604	1,910,60
	-	49,692,80
TOTAL CONSUMER STAPLES	-	701,948,542
ENERGY - 4.1%		
Dil, Gas & Consumable Fuels - 4.1%		
Antero Resources Corp. (a)	13,200	303,99
Birchcliff Energy Ltd. (e)	174,434	1,032,31
Canadian Natural Resources Ltd.	538,900	30,297,99
Cheniere Energy, Inc.	220,000	33,519,20
Chevron Corp.	591,000	92,993,85
ConocoPhillips Co.	1,064,600	110,303,20
Diamondback Energy, Inc.	15,200	1,996,67
EOG Resources, Inc.	230,000	26,321,20
Exxon Mobil Corp.	2,262,000	242,599,50
Hess Corp.	342,413	46,551,04
Marathon Petroleum Corp.	410,700	47,887,62
Occidental Petroleum Corp.	753,762	44,321,20
PDC Energy, Inc.	576,000	40,976,64
Pioneer Natural Resources Co.	46,700	9,675,30
PrairieSky Royalty Ltd.	62,700	1,096,15
Reliance Industries Ltd.	91,881	2,863,37
Suncor Energy, Inc.	76,400	2,241,10
Tourmaline Oil Corp.	54,412	2,563,80
Valero Energy Corp.	550,033 _	64,518,87
	-	802,063,06
FINANCIALS - 12.3%		
Banks - 2.4%	047 100	1 450 000
AIB Group PLC Banco Santander SA (Spain)	347,100	1,458,20
	1,399,600	5,181,51 88 750 99
Bank of America Corp. Bank of Ireland Group PLC	3,093,447	88,750,99
East West Bancorp, Inc.	519,000 85,700	4,948,61 4,524,10
East west Bancorp, inc. First Citizens Bancshares, Inc.	2,500	4,524,10 3,208,62
First Cinzens Bancshares, Inc. IPMorgan Chase & Co.	2,500 1,738,539	3,208,62
Nu Holdings Ltd. (a)	1,157,000	9,128,73
Royal Bank of Canada	622,900	59,489,94
Starling Bank Ltd. Series D (a)(b)(c)	2,643,467	9,803,03
Wells Fargo & Co.	2,643,487 610,100 _	26,039,06
	010,100 _	
		465 385 95
-	-	465,385,95
Capital Markets - 1.9% Ameriprise Financial, Inc.	- 151,000	<u>465,385,95</u> 50,156,16

Common Stocks – continued Shares Value (\$) FINANCIALS - continued Capital Markets – continued Brookfield Asset Management Ltd. Class A 6,417 209,452 Brookfield Corp. (Canada) Class A 41.900 1,410,636 Goldman Sachs Group, Inc. 3,600 1,161,144 Morgan Stanley 113,274,560 1,326,400 MSCI. Inc. 254,828 119,588,232 S&P Global, Inc. 142,400 57,086,736 State Street Corp. 357,500 26,161,850 39,300 T. Rowe Price Group, Inc. 4,402,386 374,004,068 Consumer Finance - 0.2% American Express Co. 168.600 29,370,120 Financial Services - 6.0% Adyen BV (a)(d) 4,062 7,034,034 Berkshire Hathaway, Inc. Class B (a) 2,380,188 811,644,108 323,300 MasterCard, Inc. Class A 127,153,890 PayPal Holdings, Inc. (a) 50,000 3,336,500 Visa, Inc. Class A 937,200 222,566,256 1,171,734,788 Insurance - 1.8% American International Group, Inc. 518,911 29,858,139 Aon PLC 8,000 2,761,600 Arthur J. Gallaaher & Co. 455,300 99,970,221 Brookfield Asset Management Reinsurance Partners Ltd. 2.671 90.367 Chubb Ltd. 250,800 48,294,048 Fairfax Financial Holdings Ltd. (sub. vtg.) 10,100 7,565,298 Hartford Financial Services Group, Inc. 58,612 4,221,236 Intact Financial Corp. 127,900 19,747,625 Marsh & McLennan Companies, Inc. 78,800 14,820,704 550,500 72,869,685 Progressive Corp. 232,900 The Travelers Companies, Inc. 40,445,414 340,644,337 TOTAL FINANCIALS 2,381,139,263 HEALTH CARE - 15.7% Biotechnology - 3.4% Alnylam Pharmaceuticals, Inc. (a) 61,103 11,605,904 Argenx SE ADR (a) 38,702 15,083,330 Arrowhead Pharmaceuticals, Inc. (a) 32,400 1,155,384 Biogen, Inc. (a) 3,400 968,490 Biohaven Ltd. 4,312 103,143 Exact Sciences Corp. (a) 26,800 2,516,520 Galapagos NV sponsored ADR (a) 149,784 6,090,217 Gilead Sciences, Inc. 502,000 38,689,140 Intellia Therapeutics, Inc. (a) 12.052 491.481 Krystal Biotech, Inc. (a) 9,600 1,127,040 Legend Biotech Corp. ADR (a) 142,500 9,836,775 Moderna, Inc. (a) 444,362 53,989,983 Moonlake Immunotherapeutics (a) 44,200 2,254,200 Nuvalent, Inc. Class A (a) 47.300 1,994,641 Regeneron Pharmaceuticals, Inc. (a) 402,741 289,385,518 Roivant Sciences Ltd. (a) 248,700 2,506,896 Sarepta Therapeutics, Inc. (a) 10,500 1,202,460

See accompanying notes which are an integral part of the financial statements.

1,116,268

5,800

Seagen, Inc. (a)

Shares Value (\$) HEATH CARE – continued Biotechnology – continued 102,844 22,702,813 Wetex Phomecentics, Inc. (a) 577,700 203,278,407 203,278,407 Zie Lieb Ltd. (a) 445,770 12,226,478 667,345,088 Headh Care Equipment & Supplies - 1.4% Main Technology, Inc. (a) 32,000 32,833,200 Boxter International, Inc. 720,000 32,833,200 33,932,849 Edwards Lifesciences Corp. (a) 67,74,800 31,909,1932 32,833,200 Boxter International, Inc. 720,000 32,833,200 32,833,200 Boxter International, Inc. (a) 319,118 109,119,209 1,332,8409 Edwards Lifesciences Corp. (a) 428,928 40,460,778 64,7345 Braine Medical Systems, Inc. (a) 319,118 109,119,209 1,332,816 Braine Medical Systems, Inc. (a) 13,300 1,332,816 Systems, 10,232,816 Braine Maching AG 25,753 4,176,357 2,712,21,477 Perumbra, Inc. (a) 12,300 1,232,616 Systems, 10,200 1,178,555 Str	Common Stocks – continued		
Biotechnology – continued United Therapeutics (cap. (a) 102,844 22,702,813 Vertex Pharmaceuticuls, Inc. (a) 577,700 203,298,407 Zai Lab Lid. (a) 445,770 1,226,478 Health Care Equipment & Supplies - 1.4% Align Technology, Inc. (a) 3,200 1,131,648 Boarter International, Inc. 720,000 32,803,200 Boarter International, Inc. 720,000 32,803,200 Boarter International, Inc. 720,000 32,804,079 Boarter International, Inc. 720,000 32,804,079 Edwards: Lifesciences Carp. (a) 428,928 40,460,778 Boarter International, Inc. (a) 428,928 40,460,778 Edwards: Lifesciences Carp. (a) 428,928 40,460,778 Boarter, Inc. (a) 1,978,928 40,460,778 Edwards: Lifesciences Carp. (a) 428,928 40,460,778 Boarter, Inc. (a) 1,920,923,216 Penumbra, Inc. (a) 3,600 1,278,616 1,923,921,216 1,923,921,216 Structure Netical, Inc. (a) 3,600 2,250,732 1,76,357 1,76,357 1,76,357 1,76,857 2,71,221,477 <	Common Slocks - commuea	Shares	Value (\$)
United Therapeutics Corp. (a) 102,844 22,702,813 Vetue Pharmaceuticals, Inc. (a) 577,700 203,278,407 Zai Lab Ltd. (a) 445,770 1.226,478 Health Care Equipment & Supplies - 1.4% Align Technology, Inc. (a) 3,200 1,131,448 Backer International, Inc. 720,000 32,2803,200 32,803,200 Backer International, Inc. 720,000 32,2803,200 32,803,200 Backer International, Inc. 65,925 5,555,474 31,991,932 DexKom, Inc. (a) 428,928 40,460,778 65,925 5,555,474 Intuitive Surgical, Inc. (a) 10,911,800 1,023,216 Penumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockwow Medical, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 5,176,374 1,78,555 Straumann Holding AG 25,750 2,7802,732 1,78,555 2,71,224,777 Health Care Providers & Services - 4.3% 010,952,906 2,7802,737 1,718,555 2,71,727 1,725,532,794	HEALTH CARE – continued		
United Therapeutics Corp. (a) 102,844 22,702,813 Vetue Pharmaceuticals, Inc. (a) 577,700 203,278,407 Zai Lab Ltd. (a) 445,770 1.226,478 Health Care Equipment & Supplies - 1.4% Align Technology, Inc. (a) 3,200 1,131,448 Backer International, Inc. 720,000 32,2803,200 32,803,200 Backer International, Inc. 720,000 32,2803,200 32,803,200 Backer International, Inc. 65,925 5,555,474 31,991,932 DexKom, Inc. (a) 428,928 40,460,778 65,925 5,555,474 Intuitive Surgical, Inc. (a) 10,911,800 1,023,216 Penumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockwow Medical, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 5,176,374 1,78,555 Straumann Holding AG 25,750 2,7802,732 1,78,555 2,71,224,777 Health Care Providers & Services - 4.3% 010,952,906 2,7802,737 1,718,555 2,71,727 1,725,532,794	Piotochnology continued		
Vertex Pharmoceuticals, Inc. (a) 577,700 203,298,407 Zai Lab Lid. (a) 1,226,478 667,345,088 Headh Care Equipment & Supplies - 1.4% Align Technology, Inc. (a) 3,200 1,131,648 Boxter International, Inc. 720,000 32,803,200 Boxtor Scientific, Gop. (a) 574,800 31,090,932 Dextor, Inc. (a) 25,900 3,284,092 Edwards Lifesciences Cop. (a) 428,928 40,460,778 GE Healthcare Holding LLC 65,925 5,557,471 Inspire Medical Systems, Inc. (a) 4,000 1,288,660 Intuitive Surgical, Inc. (a) 1,2300 1,032,216 Penumbra, Inc. (a) 1,2300 1,032,216 Penumbra, Inc. (a) 8,300 2,468,903 Straumon Holding AG 2,5753 4,176,357 Straumon Holding AG 2,5750 4,176,357 Straumon Holding, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Headth, Inc. (a) 140,000 16,616,446 Holding, Inc. (a) 12,700		102 844	22 702 813
Zai Lab Ltd. (a) 445,770 1.226,478 Health Care Equipment & Supplies - 1.4% 667,345,088 Mign Technology, Inc. (a) 3,200 1,131,648 Boxter International, Inc. 720,000 32,803,200 Boxter International, Inc. 720,000 32,803,200 Boxter International, Inc. (a) 54,800 31,979,932 DexCorn, Inc. (a) 428,928 40,460,778 GE HealthCare Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 4,000 1,228,560 Intuitive Surgical, Inc. (a) 1,032,216 100,172,23 Inspire Medical, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 22,173,241 Stockwave Medical, Inc. (a) 3,600 1,238,616 Struamonn Holding A6 25,753 4,176,357 Struamonn Holding A6 25,753 4,176,357 Struamon Holding, Inc. 104,070 13,305,999 Struamon Holding, Inc. 129,800 2,250,732 AmerisourceBergen Corp. 2,500 1,178,565 Cardinal Heal		•	
4667.345.088 Health Care Equipment & Supplies - 1.4% Align Technology, Inc. (a) Backer International, Inc. 2000 Baster International, Inc. 2100 Baster International, Inc. 22,000 Baster International, Inc. 22,000 Baster International, Inc. 22,000 Baster International, Inc. 22,000 Baster International, Inc. (a) 22,000 Baster International, Inc. (a) 22,000 1111 22,000 22,000 22,000 23,000 22,000 24,001 24,001 24,001 24,001 24,001 24,001 24,001 24,001 25,001 23,001 23,001 23,001 23,001 23,001 24,001 24,001 24,001		•	
Align Technology, Inc. (a) 3,200 1,131,648 Baxter International, Inc. 720,000 32,803,200 Boston Scientific Corp. (a) 574,800 31,090,932 Boston Scientific Corp. (a) 428,928 40,460,778 GE Healthcare Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 4,000 1,288,560 Inutritive Surgical, Inc. (a) 10,32,216 Penumbra, Inc. (a) 34,010 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockware Medical, Inc. (a) 3,300 2,368,903 Strugenan Heideling AG 25,753 4,176,357 Strugenan Heideling AG 25,753 4,176,357 Strugenan Heideling AG 22,700 1,178,565 Zuri Zeit AF 27,1251,477 178,356 aglion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 14,0700 16,616,446 HCA Holdings, Inc. (a) 12,700 1,029,970 McKeson Corp. 141,000 60,250,710 Mediar Partners, Inc. Class A (a) <td></td> <td>-</td> <td></td>		-	
Baxter International, Inc. 720,000 32,803,200 Boston Scientific Corp. (a) 574,800 3),090,932 DexCorn, Inc. (a) 25,900 3,28,403 Dewords Lifexciences Corp. (a) 428,228 40,460,778 GE Healthcare Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 40,000 1,278,560 Intuitive Surgical, Inc. (a) 10,91,192,000 1,323,216 Perumbra, Inc. (a) 3,600 1,238,616 Reskled, Inc. 119,786 26,173,241 Strutumenn Holding AG 25,753 4,176,357 Struker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 2,250,732 1,178,565 271,251,477 Health Care Providers & Services - 4.3% 2,250,732 agion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,997 Health Care Providers & Services - 4.3% 21,251,271 21,253,709 Elevance Health, Inc. 140,700 10,250,7			
Boston Scientific Corp. (a) 574,800 31,090,932 DexCorn, Inc. (a) 25,900 3,328,409 Edwards Lifesciences Corp. (a) 428,928 40,460,778 GE Healthoren Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 4,000 1,278,560 Institive Surgical, Inc. (a) 12,300 1,032,216 Penumbra, Inc. (a) 12,300 1,238,616 ResNed, Inc. 119,766 62,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Struumann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 22,207,032 2,712,21,477 Health Care Providers & Services - 4.3% quality in the control in the structure of the structure			
DexCom, Inc. (a) 25,900 3,328,409 Edwards Lifesciences Corp. (a) 428,928 40,460,778 GE Healthcare Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 19,118 109,119,209 Lanthives Surgical, Inc. (a) 12,300 1,032,216 Penumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Struumann Holding AG 25,753 4,176,357 Struker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 galion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. (a) 12,700 1,029,970 Mckesson Corp. 141,000 60,250,710 P3 Health Care Technology - 0.0% 33,68,97,589 Daximity, Inc. (a) (e) 64,100 2,180,682 Schordinger, Inc. (a) (e)			
Edwards Lifesciences Corp. (a) 428,928 40,460,778 GF Healthcare Holding LLC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 4,000 1,228,560 Inthitive Surgical, Inc. (a) 119,170 119,209 Lantheus Holdings, Inc. (a) 12,300 1,032,216 Penumbra, Inc. (a) 3,600 1,238,616 RestMed, Inc. 119,786 26,173,241 Shockwore Medical, Inc. (a) 8,300 2,368,903 Strummann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,475,096 Surgical Science Sweden AB (a) 52,700 1,178,565 271,251,477 Health Care Providers & Services - 4.3% 0 oglion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. (a) 129,800 2,250,732 Hearth Care Providers & Services - 4.3% 0 10,4700 13,305,999 Elevance Health, Inc. (a) 12,070 1,029,970 McKesson Corp. 141,000 60,250,710	•		
GE Heulthcare Holding LIC 65,925 5,355,747 Inspire Medical Systems, Inc. (a) 1,000 1,298,560 Intuitive Surgical, Inc. (a) 10,312,118 109,119,209 Lantheus Holdings, Inc. (a) 1,032,216 Perumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Stroumann Holding AG 25,753 4,176,337 517,477 535 Stroger Corp. 34,400 10,495,096 271,251,477 Health Care Providers & Services - 4.3% 21,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 140,700 13,305,999 Heauth Care Providers & Cars A (a) 12,4871 373,364 10,22,970 Markeson Corp. 141,000 60,20,710 10,22,970 Markeson Corp. 141,000 3,0075,072 5,255,754 Doximity, Inc. (a) (le) 64,100 2,180,618 3,276,072 Doximity, Inc. (a) (le) 64,100 <t< td=""><td></td><td></td><td></td></t<>			
Inspire Medical Systems, Inc. (a) 4,000 1,298,560 Intuitive Sugical, Inc. (a) 319,118 109,119,209 Lamthes Woldings, Inc. (a) 1,2300 1,032,216 Penumbra, Inc. (a) 3,600 1,238,616 ResNded, Inc. 119,766 26,713,241 Shockwove Medical, Inc. (a) 8,300 2,368,903 Strummann Holding AG 25,753 4,176,357 Stryker Cop. 34,400 10,495,096 Surgical Science Sweden AB (a) 2,270,232 7,125,1477 Health Care Providers & Services - 4.3% 2,7400 12,646,644 Cardinal Health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Cop. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Bevance Health, Inc. 140,700 10,229,710 McKesson Cop. 12,700 1,022,970 McKesson Cop. 141,000 60,250,710 Parter Scientific, Inc. (a) 1,71,253,944 33,364 UnitedHealth Group, Inc. 1,513,740 72,7253,994 Doximm	•		
Intuitive Surgical, Inc. (a) 319,118 109,119,209 Lantheus Holdings, Inc. (a) 12,300 1,032,216 Perumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. 119,786 26,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Struumann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 Z71,251,477 Health Care Providers & Services - 4.3% 21,125,500 galion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. (a) 140,700 13,305,999 Elevance Health, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 Phenry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 Phealth Care Technology - 0.0% - - Davimity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a)(
Lantheus Holdings, Inc. (a) 12,300 1,232,216 Penumbra, Inc. (a) 3,600 1,238,616 ResMed, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 Stryker Cop. 34,400 10,495,096 Stryker Cop. 34,400 10,495,096 Stryker Cop. 34,400 10,495,096 Stryker Cop. 34,400 10,495,096 Stryker Cop. 11,78,565 271,251,477 Health Care Providers & Services - 4.3% agilon health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,444 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Closs A (a) 124,871 373,364 UnitedHealth Forup, Inc. 1,513,740 <u>727,563,994</u> Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 7,774 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 <u>7,934,883</u> <u>318,911,933</u> Pharmaceuticals - 4.9% AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Wyers Squibb Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,000 3,553,87 Wearke & Co., Inc. (a) (25,585 40,031 Now Nordisk A/S Series B 22,000 3,553,87 Nourdion Bi, Inc. (a) 255,858 40,031 Now Nordisk A/S Series B 22,000 3,553,87 Nourdion Bi, Inc. (a) 255,858 40,1853 Royalty Pharma PLC			
Penumbro, Inc. (a) 3,600 1,238,616 Res/Med, Inc. 119,786 26,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 Verther Medital, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 41,267 12,523,709 Hearth Care Providers & Services - 4.3% 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 <u>727,563,994</u> Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schro			
ResMed, Inc. 119,786 26,173,241 Shockwave Medical, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,4495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 Zy71,251,477 Health Care Providers & Services - 4.3% agilon health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 140,700 13,305,999 12,2700 1,029,970 McKesson Corp. 141,000 60,250,710 10,299,70 McKesson Corp. 141,000 60,250,710 12,700 P3 Health Portners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 <u>727,563,994</u> Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Danaher Corp. 592,397 142,175,280 Metthe-Toledo International, Inc. (a) 27,074 35,511			
Shockwave Medical, Inc. (a) 8,300 2,368,903 Straumann Holding AG 25,753 4,176,357 Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 Peter Providers & Services - 4.3% agilon health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 2,7400 16,616,446 ICA Holdings, Inc. 140,700 13,305,999 Elevance Health, Inc. (a) 12,270 1,029,970 McKesson Corp. 141,000 60,250,710 93,334,40 10,4267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 12,760 1,272,563,994 836,897,589 Health Care Technology - 0.0% 2 5,257,54 142,175,280 Davimity, Inc. (a) (e) 61,600 3,025,57,54 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 3 318,9	•	•	
Straumann Holding A6 25,753 4,176,357 Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 galion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 41,267 12,523,709 Health Care Providers & Carp. 141,000 60,250,710 P3 Health Partmers, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 -727,563,994 Mackesson Corp. 141,000 60,250,710 P3 Health Partmers, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 -727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schoodinger, Inc. (a) (e) 64,100 2,180,682 Schoodinger, Inc. (a) (e) 142,175,280 31,891,933 Partmaceuticals - 4.9% 31,819,11,33 -7,974 AstraZeneca PLC sponsored ADR 127,600 9,132,332	,		
Stryker Corp. 34,400 10,495,096 Surgical Science Sweden AB (a) 52,700 1,178,565 galion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Beurace Health, Inc. 41,267 12,523,709 Hearth Mealth, Inc. 41,267 12,523,709 Hearth Pathers, Inc. (a) 12,400 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Pathers, Inc. Closs A (a) 124,871 373,334 UnitedHealth Group, Inc. 1,513,740			
Lenth Care Providers & Services - 4.3% 271,251,477 ugion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,252,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 592,397 142,175,280 Mettle-Toledo International, Inc. (a) 77,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 ShtaZeneace PLC sponsored ADR 127,600 9	Stryker Corp.		
Health Care Providers & Services - 4.3% agilon health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Doximity, Inc. (a) (e) 61,600 3,075,072 Schrodinger, Inc. (a) (e) 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 Bristol-Myers Squibb Co. 1,258,553 590,236,186 <t< td=""><td>Surgical Science Sweden AB (a)</td><td>52,700</td><td>1,178,565</td></t<>	Surgical Science Sweden AB (a)	52,700	1,178,565
agion health, Inc. (a) 129,800 2,250,732 AmerisourceBergen Cop. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 592,397 142,175,280 Mether Corp. 592,397 142,175,280 Mether Corp. 592,397 142,175,280 Mether Sciences Tools & Services - 1.7% 318,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 33,290,429 V		-	271,251,477
AmerisourceBergen Corp. 15,500 2,982,665 Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 <u>727,563,994</u> Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 592,397 142,175,280 Mattle-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 <td></td> <td>100.000</td> <td>0.050.700</td>		100.000	0.050.700
Cardinal Health, Inc. 140,700 13,305,999 Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Jozansky, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 J18,911,933 7,934,883 318,911,933 Pharmaceuticals - 4.9% 430,000 27,498,500			
Elevance Health, Inc. 37,400 16,616,446 HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Doximity, Inc. (a) (e) 61,600 3,075,072 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 318,911,933 Pharmaceuticals - 4.9% 12,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 <td< td=""><td></td><td></td><td></td></td<>			
HCA Holdings, Inc. 41,267 12,523,709 Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Life Sciences Tools & Services - 1.7% Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 3130,900 27,498,500 21,290,00 27,498,500 DICE Therapeutics, Inc. (a) 77,130 4,883,872 Johnson 212,900 35,239,208 Intro-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Serie		•	
Henry Schein, Inc. (a) 12,700 1,029,970 McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740			
McKesson Corp. 141,000 60,250,710 P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Doximity, Inc. (a) (e) 61,600 3,075,072 Life Sciences Tools & Services - 1.7% Danaher Corp. 592,397 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 313,000 27,498,500 DICE Therapeutics, Inc. (a) 127,600 9,132,332 590,236,186 Intro-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,31 Novo Nordisk A/S Series B 22,000 3,553,877 Novation Bio, Inc. (a)			
P3 Health Partners, Inc. Class A (a) 124,871 373,364 UnitedHealth Group, Inc. 1,513,740 727,563,994 Boximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Doximity, Inc. (a) (e) 61,600 3,075,072 Life Sciences Tools & Services - 1.7% 700 35,511,341 Dandher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a)(b)(c)(f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 330,000 27,498,500 DICE Therapeutics, Inc. (a) 127,600 9,132,332 313,291 Bristol-Myers Squibb Co. 430,000 27,498,500 21,2900 35,239,208 Intro-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 25,571,653 461,853 <td>• •</td> <td>•</td> <td></td>	• •	•	
UnitedHealth Group, Inc. 1,513,740 727,563,994 836,897,589 Health Care Technology - 0.0% 0 Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 33,000 27,498,500 DICE Therapeutics, Inc. (a) 127,600 9,132,332 590,236,186 Intro-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,31 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 25,571,653 461,853 831,869 25,571,653		•	
Health Care Technology - 0.0% 836,897,589 Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Experiment Corp. 61,600 3,075,072 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 Pharmaceuticals - 4.9% 318,911,933 7,934,883 Pharmaceuticals - 4.9% 430,000 27,498,500 DICE Therapeutics, Inc. (a) 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,311 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 25,571,653 461,853			•
Doximity, Inc. (a) (e) 64,100 2,180,682 Schrodinger, Inc. (a) (e) 61,600 3,075,072 Life Sciences Tools & Services - 1.7% 592,397 Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133			
Schrödinger, Inc. (a) (e) 61,600 3,075,072 Life Sciences Tools & Services - 1.7% Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133		(4.100	0 100 /00
5,255,754 Life Sciences Tools & Services - 1.7% Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 25,571,653 461,853 Royalty Pharma PLC 831,869 25,571,653			
Life Sciences Tools & Services - 1.7% Danaher Corp. 592,397 142,175,280 Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 <u>7,934,883</u> AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 25,571,653 461,853	Schrödinger, Inc. (d) (e)	61,600	
Mettler-Toledo International, Inc. (a) 27,074 35,511,341 Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 318,911,933 Pharmaceuticals - 4.9% 318,911,933 AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653	Life Sciences Tools & Services - 1.7%	-	J,2JJ,7J4
Thermo Fisher Scientific, Inc. 255,468 133,290,429 Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9% 318,911,933 Pharmaceuticals - 4.9% 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653	Danaher Corp.	592,397	142,175,280
Veterinary Emergency Group LLC Class A (a) (b) (c) (f) 147,133 7,934,883 318,911,933 Pharmaceuticals - 4.9%	Mettler-Toledo International, Inc. (a)	27,074	35,511,341
318,911,933 Pharmaceuticals - 4.9% AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653		255,468	133,290,429
Pharmaceuticals - 4.9% AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653	Veterinary Emergency Group LLC Class A (a) (b) (c) (f)	147,133	
AstraZeneca PLC sponsored ADR 127,600 9,132,332 Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653	Phannan timela 4 00/	-	318,911,933
Bristol-Myers Squibb Co. 430,000 27,498,500 DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653		127 / 00	0 1 2 2 2 2 2 2
DICE Therapeutics, Inc. (a) 87,500 4,065,250 Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653			
Eli Lilly & Co. 1,258,553 590,236,186 Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653			
Intra-Cellular Therapies, Inc. (a) 77,130 4,883,872 Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653	•		
Johnson & Johnson 212,900 35,239,208 Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653			
Merck & Co., Inc. 1,862,900 214,960,031 Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653		•	
Novo Nordisk A/S Series B 22,000 3,553,877 Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653			
Nuvation Bio, Inc. (a) 256,585 461,853 Royalty Pharma PLC 831,869 25,571,653			
		256,585	
Structure Therapeutics, Inc. ADR 71,600 2,976,412		831,869	25,571,653
	Structure Therapeutics, Inc. ADR	71,600	2,976,412

Common Stocks - continued Shares Value (\$) HEALTH CARE - continued Pharmaceuticals - continued Ventyx Biosciences, Inc. (a) 29,800 977,440 Verona Pharma PLC ADR (a) 26.400 558,096 186,000 32,031,060 Zoetis, Inc. Class A 952,145,770 TOTAL HEALTH CARE 3,051,807,611 **INDUSTRIALS - 5.1%** Aerospace & Defense - 0.8% Lockheed Martin Corp. 126,800 58,376,184 Northrop Grumman Corp. 142,800 65,088,240 175,917 Space Exploration Technologies Corp. Class A (a) (b) (c) 14,249,277 TransDigm Group, Inc. 14,400 12,876,048 150,589,749 Air Freight & Logistics - 0.3% United Parcel Service, Inc. Class B 317,500 56,911,875 Zipline International, Inc. (a) (b) (c) 2,029,256 50,479 58,941,131 **Building Products - 0.4%** Carrier Global Corp. (e) 933,000 46,379,430 Toto Ltd. 415,900 12,575,323 Trane Technologies PLC 97,620 18,670,801 77,625,554 Commercial Services & Supplies - 0.2% Cintas Corp. 17.025 8,462,787 Clean Harbors, Inc. (a) 77,590 12,758,124 Clean TeQ Water Pty Ltd. (a) 3,117 498 Copart, Inc. (a) 160,700 14,657,447 GFL Environmental, Inc. 34,200 1,327,985 23,200 Republic Services, Inc. 3,553,544 Waste Connections, Inc. (United States) 7,700 1,100,561 41,860,946 Construction & Engineering - 0.1% Larsen & Toubro Ltd. 40,600 1,227,362 Quanta Services, Inc. 78,733 15,467,098 16,694,460 **Electrical Equipment - 0.4%** AMETEK, Inc. 86,900 14,067,372 Eaton Corp. PLC 174,200 35,031,620 Hubbell, Inc. Class B 73,357 24,322,247 nVent Electric PLC 84,100 4,345,447 Prysmian SpA 28,300 1,182,123 78,948,809 Ground Transportation - 0.6% Canadian Pacific Kansas City Ltd. 504,300 40,732,289 J.B. Hunt Transport Services, Inc. 43,841 7,936,536 Old Dominion Freight Lines, Inc. 155,320 57,429,570 Uber Technologies, Inc. (a) 182,100 7,861,257 Vamos Locacao de Caminhoes Maquinas e Equipamentos SA 24,400 61,711 114,021,363 Industrial Conglomerates - 0.5% General Electric Co. 922,677 101,356,068 Machinery - 1.3%

88,800

21,849,240

See accompanying notes which are an integral part of the financial statements.

Caterpillar, Inc.

Schedule of Investments (Unaudited) - Continued

Common Stocks – continued	Shares	Value (\$)
INDUSTRIALS — continued		
Machinery — continued		
Crane Nxt Co.	9,200	519,248
Deere & Co.	118,600	48,055,534
Fortive Corp.	77,000	5,757,290
Indutrade AB	46,600	1,049,492
Otis Worldwide Corp.	386,700	34,420,167
PACCAR, Inc.	735,195	61,499,062
Parker Hannifin Corp.	189,500 _	73,912,580 247,062,613
Passenger Airlines - 0.1%	-	
Copa Holdings SA Class A	20,400	2,255,832
Ryanair Holdings PLC sponsored ADR (a)	90,200	9,976,120
	-	12,231,952
Professional Services - 0.0%	14//5	1 070 000
Thomson Reuters Corp.	14,665	1,979,983
Verisk Analytics, Inc.	36,300 _	<u>8,204,889</u> 10,184,872
Trading Companies & Distributors - 0.4%	-	10,104,072
United Rentals, Inc.	24,600	10,956,102
W.W. Grainger, Inc.	87,632	69,105,719
The ordinger, me.		80,061,821
TOTAL INDUSTRIALS	-	989,579,338
INFORMATION TECHNOLOGY - 30.6%	-	107,511,000
Communications Equipment - 0.6%		
Arista Networks, Inc. (a)	266,174	43,136,158
Cisco Systems, Inc.	1,211,100	62,662,314
Motorola Solutions, Inc.	11,900 _	<u>3,490,032</u> 109,288,504
Electronic Equipment, Instruments & Components - 1.4%	-	107,200,304
Amphenol Corp. Class A	2,797,131	237,616,278
CDW Corp.	114,316	20,976,986
Jabil, Inc.	63,800 _	6,885,934
	-	265,479,198
IT Services - 0.8%	441 007	10/ 00/ 00/
Accenture PLC Class A	441,397	136,206,286
Cloudflare, Inc. (a)	1,000	65,370
Gartner, Inc. (a)	14,691	5,146,404
MongoDB, Inc. Class A (a)	14,700 53,700	6,041,553
Okta, Inc. (a)	•	3,724,095
Shopify, Inc. Class A (a)	95,500	6,172,266
X Holdings Corp. Class A (c)	55,300 _	<u>2,141,216</u> 159,497,190
Semiconductors & Semiconductor Equipment - 9.2%	-	
Advanced Micro Devices, Inc. (a)	899,273	102,436,187
Advantest Corp.	23,900	3,218,948
Allegro MicroSystems LLC (a)	82,200	3,710,508
Analog Devices, Inc.	703,339	137,017,471
Applied Materials, Inc.	32,400	4,683,096
ASML Holding NV (depository receipt)	97,900	70,953,025
Broadcom, Inc.	198,400	172,098,112
First Solar, Inc. (a)	63,000	11,975,670
	63,000 215,000 133,200	11,975,670 104,279,300 85,628,952

	Shares	Value (\$)
INFORMATION TECHNOLOGY – continued		
Semiconductors & Semiconductor Equipment —		
continued		
Lattice Semiconductor Corp. (a)	290,981	27,954,54
Microchip Technology, Inc. Monolithic Power Systems, Inc.	13,900 92,450	1,245,30 49,944,26
NVIDIA Corp.	1,816,640	768,475,05
NXP Semiconductors NV	42,600	8,719,36
DN Semiconductor Corp. (a)	1,357,696	128,410,88
Qualcomm, Inc.	483,717	57,581,67
Synaptics, Inc. (a)	20,156	1,720,91
Taiwan Semiconductor Manufacturing Co. Ltd.		
sponsored ADR	353,600	35,685,31
Texas Instruments, Inc.	63,600	<u> </u>
Software - 12.5%		1,/0/,10/,00
Adobe, Inc. (a)	217,200	106,208,62
ANSYS, Inc. (a)	3,200	1,056,86
Autodesk, Inc. (a)	103,200	21,115,75
Cadence Design Systems, Inc. (a)	627,121	147,072,41
Check Point Software Technologies Ltd. (a)	44,000	5,527,28
Clear Secure, Inc. (e)	189,247	4,384,85
Dynatrace, Inc. (a)	160,800	8,276,37
Fortinet, Inc. (a)	1,771,028	133,872,00
HubSpot, Inc. (a)	7,600	4,043,88
Intuit, Inc.	7,532	3,451,08
Microsoft Corp. Rela Alta Naturaka, Inc. (a)	5,040,300	1,716,423,76
Palo Alto Networks, Inc. (a) Roper Technologies, Inc.	47,400 86,500	12,111,17 41,589,20
Salesforce, Inc. (a)	788,538	166,586,53
Samsara, Inc. (a)	9,400	260,47
ServiceNow, Inc. (a)	32,502	18,265,14
Stripe, Inc. Class B (a) (b) (c)	74,500	1,499,68
Synopsys, Inc. (a)	103,200	44,934,31
Fanium, Inc. Class B (a)(b)(c)	350,002	2,765,01
		2,439,444,45
Technology Hardware, Storage & Peripherals - 6.1%		
Apple, Inc.	6,120,700	1,187,232,17
Dell Technologies, Inc.	24,627	1,332,56
Samsung Electronics Co. Ltd.	20,950	1,153,64
		1,189,718,39
TOTAL INFORMATION TECHNOLOGY		5,950,615,60
MATERIALS - 2.1%		
Chemicals - 0.1%		
Air Products & Chemicals, Inc.	31,600	9,465,14
Corteva, Inc.	37,300	2,137,29
Linde PLC	9,200	3,505,93
Sherwin-Williams Co.	14,335	3,806,22
Westlake Corp.	76,956	9,193,93
Construction Materials - 0.0%		28,108,53
Vulcan Materials Co.	16,100	3,629,58
Metals & Mining - 2.0%		
Agnico Eagle Mines Ltd. (Canada)	19,100	953,73

Common Stocks – continued	Shares	Value (\$)
MATERIALS — continued		
Metals & Mining — continued		
B2Gold Corp.	1,582,473	5,638,251
Barrick Gold Corp. (Canada)	109,309	1,849,115
Cleveland-Cliffs, Inc. (a)	288,100	4,828,556
Franco-Nevada Corp.	776,455	110,664,253
Freeport-McMoRan, Inc. Glencore PLC	1,211,872 695,000	48,474,880 3,940,571
Ivanhoe Electric, Inc.	70,900	924,536
Ivanhoe Mines Ltd. (a)	1,893,900	17,298,502
Lundin Gold, Inc.	4,600	55,037
Newcrest Mining Ltd.	63,403	1,131,009
Novagold Resources, Inc. (a)	62,678	248,394
Nucor Corp.	523,187	85,792,204
Orla Mining Ltd. (a)	1,224,700	5,140,088
POSCO sponsored ADR (e)	5,502	406,873
Steel Dynamics, Inc.	753,731	82,103,918
Wheaton Precious Metals Corp.	304,336	13,161,283
		382,611,208
TOTAL MATERIALS		414,349,328
REAL ESTATE - 0.0%		
Equity Real Estate Investment Trusts (REITs) - 0.0%		
Equity Commonwealth	138,400	2,803,984
VICI Properties, Inc.	18,800	590,884
		3,394,868
UTILITIES - 0.6%		
Electric Utilities - 0.6%		
Constellation Energy Corp.	237,556	21,748,252
NextEra Energy, Inc.	1,100,000	81,620,000
PG&E Corp. (a)	722,100	12,477,888
		115,846,140
TOTAL COMMON STOCKS		
(Cost \$9,449,251,430)		18,804,841,498
Preferred Stocks - 0.5%		
	Shares	Value (\$)
Convertible Preferred Stocks - 0.4%		
COMMUNICATION SERVICES - 0.1% Interactive Media & Services – 0.1%		
ByteDance Ltd. Series E1 (a) (b) (c)	60,761	13,722,264
Reddit, Inc.:	00,701	13,722,204
Series E(a) (b) (c)	27,000	933,930
Series F(a) (b) (c)	85,531	2,958,517
	,	17,614,711
CONSUMER DISCRETIONARY - 0.0%		
Automobiles – 0.0%		
Rad Power Bikes, Inc.:		
Series $A(a)(b)(c)$	52,367	116,778
Series $C(a)(b)(c)$	206,059	459,512
Series D(a) (b) (c)	277,030	617,777

Value (\$)		Shares	Value (\$)
	Convertible Preferred Stocks — continued		
	CONSUMER DISCRETIONARY - continued		
5,638,251	Automobiles — continued		
1,849,115			1,194,06
4,828,556	Hotels, Restaurants & Leisure – 0.0%		
110,664,253	Discord, Inc. Series I (a) (b) (c)	2,500	768,57
48,474,880			
3,940,571	TOTAL CONSUMER DISCRETIONARY		1 049 44
924,536		-	1,962,64
17,298,502	CONSUMER STAPLES - 0.0%		
55,037	Consumer Staples Distribution & Retail – 0.0%		
1,131,009	GoBrands, Inc.:		
248,394	Series G(a) (b) (c)	5,376	487,1
85,792,204	Series $H(a)$ (b) (c)	6,820	617,96
5,140,088		0,020	1,105,02
406,873	Food Products — 0.0%	-	1,103,0
82,103,918	Bowery Farming, Inc. Series C1 (a) (b) (c)	22,172	190,67
13,161,283	bowery running, inc. Senes cr (u) (b) (c)	22,172 _	170,07
382,611,208			
414,349,328	TOTAL CONSUMER STAPLES	-	1,295,75
	FINANCIALS - 0.0%		
	Financial Services – 0.0%		
2,803,984	Circle Internet Financial Ltd. Series F (a)(b)(c)	65,587	1,577,3
590,884			
3,394,868	HEALTH CARE - 0.0%		
0,071,000	Biotechnology — 0.0%		
	ElevateBio LLC Series C (a) (b) (c)	515,200 _	2,184,4
01 740 050	Health Care Providers & Services — 0.0%		
21,748,252	Lyra Health, Inc.:		
81,620,000	Series E(a) (b) (c)	229,170	3,831,7
12,477,888	Series F(a) (b) (c)	6,800	113,6
15,846,140	Somatus, Inc. Series E (a)(b)(c)	1,539 _	1,559,4
		-	5,504,8
<u>4,841,498</u>	TOTAL HEALTH CARE	-	7,689,2
	INDUSTRIALS - 0.2%		
alue (\$)	Aerospace & Defense – 0.2%		
	Relativity Space, Inc. Series E (a)(b)(c)	208,655	3,670,2
	Space Exploration Technologies Corp. Series N		
	(a) (b) (c)	39,568	32,050,0
		-	35,720,3
	Air Freight & Logistics – 0.0%		
13,722,264	Zipline International, Inc.:		
13,722,204	Series E(a) (b) (c)	132,331	5,319,7
933,930	Series F(c)	90,550	3,640,1
		-	8,959,8
2,958,517 17,614,711	Construction & Engineering – 0.0%		
17,014,711	Beta Technologies, Inc. Series B, 6.00% (a) (b) (c)	26,772	2,902,3
			47 500 4
116,778	TOTAL INDUSTRIALS	-	47,582,4

Schedule of Investments (Unaudited) - Continued

Preferred Stocks – continued	Shares	Value (\$)
Convertible Preferred Stocks — continued		
INFORMATION TECHNOLOGY - 0.1%		
Software – 0.1% Moloco, Inc. Series A (b) (c)	44,901	2,694,060
Nuro, Inc.:	·	
Series C (a) (b) (c) Series D (a) (b) (c)	305,791 63,961	1,941,773 406,152
Stripe, Inc.: Series H(a) (b) (c)	30,400	611,952
Series I(b)(c)	203,647	4,099,414
Tenstorrent, Inc. Series C1 (a) (b) (c)	32,500	<u> </u>
TOTAL CONVERTIBLE PREFERRED STOCKS		89,392,442
Nonconvertible Preferred Stocks - 0.1%		
ENERGY - 0.1%		
Oil, Gas & Consumable Fuels — 0.1% Petroleo Brasileiro SA - Petrobras sponsored ADR	865,800	11,974,014
FINANCIALS - 0.0%		
Financial Services – 0.0%		
Circle Internet Financial Ltd. Series E (a) (b) (c)	103,462	2,488,261
TOTAL NONCONVERTIBLE PREFERRED STOCKS		14,462,275
TOTAL PREFERRED STOCKS (Cost \$86,761,848)		103,854,717
Preferred Securities – 0.0%		
	Principal Amount (g)	Value (\$)
INFORMATION TECHNOLOGY - 0.0%		
Software - 0.0%		
Tenstorrent, Inc. 0% (b) (c) (h) (Cost \$1,810,000)	1,810,000	1,795,520
Money Market Funds – 3.0%	Shares	Value (\$)
Fidelity Cash Central Fund 5.14% (i) Fidelity Securities Lending Cash Central Fund 5.14%	567,703,424	567,816,964
(i) (j)	10,528,997	10,530,050
TOTAL MONEY MARKET FUNDS (Cost \$578,342,106)		578,347,014
(00) 401 0,072,100/		<u> </u>
TOTAL INVESTMENT IN SECURITIES - 100.3%		10 400 000 740
(Cost \$10,116,165,384)		19,488,838,749
NET OTHER ASSETS (LIABILITIES) – (0.3)% NET ASSETS – 100.0%		(51,161,818) 19,437,676,931

See accompanying notes which are an integral part of the financial statements.

9

Legend				Security	Acquisition Date	Acquisition Cost (\$)		
(a)	Non-income producing			Lyra Health, Inc. Series F	6/04/21	106,790		
(b)	Restricted securities (including private pl Securities Act of 1933 (excluding 144A securities (excluding 144A issues) amou	issues). At the end of the period,	the value of restricted	Moloco, Inc. Series A	6/26/23	2,694,060		
(c)	Level 3 security			Nuro, Inc. Series C	10/30/20	3,991,979		
(d)	Security exempt from registration under be resold in transactions exempt from re the period, the value of these securities	gistration, normally to qualified ins	titutional buyers. At the end of	Nuro, Inc. Series D	10/29/21	1,333,313		
(e)	Security or a portion of the security is or	ı loan at period end.		Rad Power Bikes, Inc.	1/21/21	1,937,611		
(f)	Investment is owned by a wholly-owned tax purposes.	subsidiary (Subsidiary) that is trea	ted as a corporation for U.S.	Rad Power Bikes, Inc. Series A	Rad Power Bikes, Inc. Series A 1/21/21			
(g)	Amount is stated in United States dollars	s unless otherwise noted.		Rad Power Bikes, Inc. Series C	1/21/21	993,996		
(h)	Security is perpetual in nature with no st	tated maturity date.		Rad Power Bikes, Inc. Series D	9/17/21	2,655,000		
(i)	Affiliated fund that is generally available Fidelity Investments. The rate quoted is complete unaudited listing of the fund's	the annualized seven-day yield of t	he fund at period end. A	Reddit, Inc. Series E	5/18/21	1,146,803		
	request. In addition, each Fidelity Centra or upon request.	l Fund's financial statements are av	vailable on the SEC's website	Reddit, Inc. Series F	8/11/21	5,285,337		
(j)	Investment made with cash collateral rea	ceived from securities on loan.		Relativity Space, Inc. Series E	5/27/21	4,764,658		
				Somatus, Inc. Series E	1/31/22	1,342,985		
Additio Secur	onal information on each restricted holding i ty	is as follows: Acquisition Date	Acquisition Cost (\$)	Space Exploration Technologies Corp. Class A	2/16/21 - 5/24/22	10,018,108		
Beta 1	Technologies, Inc. Series B, 6.00%	4/04/22	2,762,067	Space Exploration Technologies Corp. Series N	8/04/20	10,683,360		
Bowe	ry Farming, Inc. Series C1	5/18/21	1,335,847	Starling Bank Ltd. Series D	6/18/21 - 4/05/22	5,186,912		
ByteD	ance Ltd. Series E1	11/18/20	6,657,837	Stripe, Inc. Class B	5/18/21	2,989,564		
Circle	Internet Financial Ltd. Series E	5/11/21	1,679,200	Stripe, Inc. Series H	3/15/21	1,219,800		
Circle	Internet Financial Ltd. Series F	5/09/22	2,763,836	Stripe, Inc. Series I	3/20/23 - 5/12/23	4,100,257		
Discor	d, Inc. Series I	9/15/21	1,376,561	Tanium, Inc. Class B	9/18/20	3,988,343		
Elevat	reBio LLC Series C	3/09/21	2,161,264	Tenstorrent, Inc. Series C1	4/23/21	1,932,265		
Epic G	iames, Inc.	7/13/20 - 7/30/20	10,838,175	Tenstorrent, Inc. 0%	4/23/21	1,810,000		
Fanati	ics, Inc. Class A	8/13/20 - 12/15/21	7,999,410	Veterinary Emergency Group LLC Class A	9/16/21 - 12/16/22	5,409,747		
GoBra	nds, Inc. Series G	3/02/21	1,342,480	Zipline International, Inc.	10/12/21	1,817,244		
GoBra	nds, Inc. Series H	7/22/21	2,649,506	Zipline International, Inc. Series E	12/21/20	4,317,881		
Lyra H	lealth, Inc. Series E	1/14/21	2,098,418					

Affiliated Central Funds

Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.

Affiliate	Value, beginning of period (S)	Purchases (S)	Sales Proceeds (S)	Dividend Income (\$)	Realized Gain (loss) (S)	Change in Unrealized appreciation (depreciation) (S)	Value, end of period (S)	% ownership, end of period
Fidelity Cash Central Fund 5.14%		2,152,718,537	2,270,363,587	11,738,769		(1)	567,816,964	1.4%
						(1)		
Fidelity Securities Lending Cash Central Fund 5.14%	7,160,500	277,063,701	273,694,151	28,821			10,530,050	0.0%
Total	692,622,515	2 <u>,429,782,238</u>	2,544,057,738	11,767,590		(1)	578,347,014	

Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds, which are presented in the corresponding line item in the Statement of Operations, if applicable.

Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities.

Amounts included in the purchases and sales proceeds columns may include in-kind transactions, if applicable.

Investment Valuation

The following is a summary of the inputs used, as of June 30, 2023, involving the Fund's assets and liabilities carried at fair value. The inputs or methodology used for valuing securities may not be an indication of the risk associated with investing in those securities. For more information on valuation inputs, and their aggregation into the levels used below, please refer to the Investment Valuation section in the accompanying Notes to Financial Statements.

Valuation Inputs at Reporting Date:									
Description	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)					
Investments in Securities:									
Equities:									
Communication Services	2,733,295,628	2,702,411,975	-	30,883,653					
Consumer Discretionary	1,680,379,461	1,617,015,222	42,666,760	20,697,479					
Consumer Staples	703,244,300	674,849,879	27,098,663	1,295,758					
Energy	814,037,081	811,173,705	2,863,376	-					
Financials	2,385,204,891	2,359,120,684	12,215,546	13,868,661					
Health Care	3,059,496,884	3,039,092,373	4,780,355	15,624,156					
Industrials	1,037,161,828	959,497,622	13,803,183	63,861,023					
Information Technology	5,962,285,806	5,939,837,094	4,372,594	18,076,118					
Materials	414,349,328	409,277,748	5,071,580	-					
Real Estate	3,394,868	3,394,868	-	-					
Utilities	115,846,140	115,846,140		-					
Preferred Securities	1,795,520	-	-	1,795,520					
Money Market Funds	578,347,014	578,347,014	<u> </u>	-					
Total Investments in Securities:	19,488,838,749	19,209,864,324	112,872,057	166,102,368					

Financial Statements (Unaudited)

Statement of Assets and Liabilities

Sidiemeni of Assels and Eddimes		June 30, 2023 (Unaudited)
Assets Investment in securities, at value (including securities loaned of \$10,407,799) — See accompanying schedule: Unaffiliated issuers (cost \$9,537,823,278) Fidelity Central Funds (cost \$578,342,106)	\$ 18,910,491,735 578,347,014	
Total Investment in Securities (cost \$10,116,165,384) Foreign currency held at value (cost \$10,614,413) Receivable for investments sold Receivable for fund shares sold Dividends receivable Distributions receivable from Fidelity Central Funds Other receivables Total assets		\$ 19,488,838,749 10,614,409 26,772,786 2,151,733 8,562,176 2,243,797 798,778 19,539,982,428
Liabilities Payable for investments purchased Payable for fund shares redeemed Accrued management fee Distribution and service plan fees payable Other affiliated payables Other affiliated payables Other payables and accrued expenses Collateral on securities loaned Total Liabilities Net Assets Net Assets Net Asset consist of: Paid in capital Total accumulated earnings (loss) Net Assets Net Asset Value and Maximum Offering Price	\$ 61,933,868 17,564,967 8,331,643 1,667,706 1,259,890 1,021,298 10,526,125	\$ <u>102,305,497</u> \$ <u>19,437,676,931</u> \$ <u>9,796,312,973</u> <u>9,641,363,958</u> \$ <u>19,437,676,931</u>
Initial Class : Net Asset Value, offering price and redemption price per share (\$8,242,102,548 ÷ 181,514,594 shares)		\$ 45.41
Service Class : Net Asset Value, offering price and redemption price per share (\$1,540,614,580 ÷ 34,171,337 shares) Service Class 2 :		\$ 45.08
Net Asset Value, offering price and redemption price per share (\$7,535,146,777 ÷ 172,308,891 shares) Investor Class :		\$ 43.73
Net Asset Value, offering price and redemption price per share (\$2,119,813,026 ÷ 47,099,478 shares)		\$ 45.01

Statement of Operations

		Six months ended June 30, 2023 (Unaudited)
Investment Income		
Dividends	\$	97,949,752
Interest		260
Income from Fidelity Central Funds (including \$28,821 from security lending)	-	11,767,590
Total Income		109,717,602
Expenses		
Management fee	\$ 47,411,445	
Transfer agent fees	6,422,533	
Distribution and service plan fees	9,438,934	
Accounting fees	746,894	
Custodian fees and expenses	91,878	
Independent trustees' fees and expenses	60,086	
Audit	47,034	
Legal	32,688	
Miscellaneous	 51,380	
Total expenses before reductions	64,302,872	
Expense reductions	 (403,743)	(0.000.100
Total expenses after reductions		63,899,129
Net Investment income (loss)		45,818,473
Realized and Unrealized Gain (Loss)		
Net realized gain (loss) on:		
Investment Securities:	0/4.050.004	
Unaffiliated issuers (net of foreign taxes of \$154,757)	264,858,084	
Foreign currency transactions	 (36,197)	0/4 001 007
Total net realized gain (loss) Change in net revealined conversition (depreciation) and		264,821,887
Change in net unrealized appreciation (depreciation) on: Investment Securities:		
Unaffiliated issuers (net of decrease in deferred foreign taxes of \$158,940)	3,135,241,741	
Fidelity Central Funds	3,135,241,741	
Unfunded commitments	491,561	
Assets and liabilities in foreign currencies	471,361 4,891	
Assers and naumines in roteign contencies Total change in net unrealized appreciation (depreciation)	 4,071	3,135,738,192
Net gain (loss)	-	3,400,560,079
Net increase (decrease) in net assets resulting from operations	, ¢	3,446,378,552
ויני וויניפאס נעפניפאסן או אפו אסטפיט ופטטאוואן ווטא טאפועווטאט	ڊ :	0,770,070,332

Statement of Changes in Net Assets

Increase (Decrease) in Net Assets		Six months ended June 30, 2023 (Unaudited)	Year ended December 31, 2022
Operations Net investment income (loss)	ć	45,818,473	\$ 75,139,230
Net realized gain (loss) Change in net unrealized appreciation (depreciation)	\$	45,010,473 264,821,887 3,135,738,192	925,407,677 (7,479,141,889)
Net increase (decrease) in net assets resulting from operations	-	3,446,378,552	(6,478,594,982)
Distributions to shareholders	-	(170,228,692)	(993,733,960)
Share transactions - net increase (decrease)	-	(709,094,561)	(551,713,564)
Total increase (decrease) in net assets	-	2,567,055,299	(8,024,042,506)
Net Assets			
Beginning of period		16,870,621,632	24,894,664,138
End of period	\$	19,437,676,931	\$ 16,870,621,632

Financial Highlights

VIP Contrafund[™] Portfolio Initial Class

	(1	Six months ended Jnaudited) June 30, 2023		Years ended December 31, 2022	2021		2020		2019	2018
Selected Per-Share Data										
Net asset value, beginning of period	\$ _	37.88	\$_	54.35 \$	48.17	\$	37.17	\$	32.13	37.94
Income from Investment Operations										
Net investment income (loss) ^{A,B}		.13		.22	.04	ŀ	.07		.16	.23
Net realized and unrealized gain (loss)	_	7.78	_	(14.37)	12.88	<u> </u>	11.24		9.15	(2.50)
Total from investment operations	_	7.91	_	(14.15)	12.92		11.31		9.31	(2.27)
Distributions from net investment income		-		(.22)	(.02)	C	(.10)		(.16)	(.26)
Distributions from net realized gain	_	(.38)	_	(2.09)	(6.72)	<u> </u>	(.21)		(4.11)	(3.28)
Total distributions	_	(.38)	_	(2.32) D	(6.74)		(.31)	_	(4.27)	(3.54)
Net asset value, end of period	\$	45.41	\$	37.88 \$	54.35	\$	48.17	\$	37.17	32.13
Total Return ^{E,F,G}	_	21.01%	-	(26.31)%	27.83%	- <u> </u>	30.57%		31.58%	(6.38)%
Ratios to Average Net Assets B.H.I										
Expenses before reductions		.60% ^J		.60%	.60%	Ď	.61%		.61%	.62%
Expenses net of fee waivers, if any		.5 9 % ^յ		.60%	.60%	Ď	.61%		.61%	.62%
Expenses net of all reductions		.5 9 % ^յ		.60%	.60%	Ď	.61%		.61%	.61%
Net investment income (loss)		.62% ^J		.50%	.08%	, j	.17%		.48%	.64%
Supplemental Data										
Net assets, end of period (000 omitted)	\$	8,242,103	\$	7,255,740 \$	10,409,645	; \$	8,916,447	\$	6,919,369	6,240,295
Portfolio turnover rate ^K		35% ^j		38%	34%	Ď	39%		37%	111%

^A Calculated based on average shares outstanding during the period.

⁸ Net investment income (loss) is affected by the timing of the declaration of dividends by any underlying mutual funds or exchange-traded funds (ETFs). Net investment income (loss) of any mutual funds or ETFs is not included in the Fund's net investment income (loss) ratio.

^c The amount shown reflects reclassifications related to book to tax differences that were made in the year shown.

^D Total distributions per share do not sum due to rounding.

^E Total returns for periods of less than one year are not annualized.

F Total returns do not reflect charges attributable to your insurance company's separate account. Inclusion of these charges would reduce the total returns shown.

⁶ Total returns would have been lower if certain expenses had not been reduced during the applicable periods shown.

* Fees and expenses of any underlying mutual funds or exchange-traded funds (ETFs) are not included in the Fund's expense ratio. The Fund indirectly bears its proportionate share of these expenses. For additional expense information related to investments in Fidelity Central Funds, please refer to the "Investments in Fidelity Central Funds" note found in the Notes to Financial Statements section of the most recent Annual or Semi-Annual report.

Expense ratios reflect operating expenses of the class. Expenses before reductions do not reflect amounts reimbursed, waived, or reduced through arrangements with the investment adviser, brokerage services, or other offset arrangements, if applicable, and do not represent the amount paid by the class during periods when reimbursements, waivers or reductions occur.

^J Annualized.

K Amount does not include the portfolio activity of any underlying mutual funds or exchange-traded funds (ETFs).

VIP Contrafund[™] Portfolio Service Class

	Six months ended aaudited) June 30, 2023	Years ended December 31, 2022	2021	2020	2019	2018
Selected Per-Share Data						
Net asset value, beginning of period	\$ 37.63	\$ <u> </u>	47.89	\$36.96	\$ 31.97	\$ 37.77
Income from Investment Operations						
Net investment income (loss) ^{A,B}	.11	.17	(.01)	.03	.13	.19
Net realized and unrealized gain (loss)	 7.72	(14.27)	12.80	11.17	9.10	(2.48)
Total from investment operations	 7.83	(14.10)	12.79	11.20	9.23	(2.29)
Distributions from net investment income	-	(.18)	(.01) ^c	(.06)	(.13)	(.22)
Distributions from net realized gain	 (.38)	(2.09)	(6.67) ⁽	(.21)	(4.11)	(3.28)
Total distributions	 (.38)	(2.27)	(6.68)	(.27)	(4.24)	(3.51) D
Net asset value, end of period	\$ 45.08	37.63 \$	54.00	\$ 47.89	\$ 36.96	\$ 31.97
Total Return ^{E,F,G}	 20.94%	(26.38)%	27.71%	30.43%	31.45%	(6.49)%
Ratios to Average Net Assets ^{B,H,I}						
Expenses before reductions	.70% ^յ	.70%	.70%	.71%	.71%	.72%
Expenses net of fee waivers, if any	.69% [」]	.70%	.70%	.71%	.71%	.72%
Expenses net of all reductions	.69% ^J	.70%	.70%	.71%	.71%	.71%
Net investment income (loss)	.52% ^յ	.40%	(.02)%	.07%	.38%	.54%
Supplemental Data						
Net assets, end of period (000 omitted)	\$ 1,540,615	5 1,326,910 \$	2,001,479	\$ 1,734,783	\$ 1,493,164	\$ 1,324,859
Portfolio turnover rate ^K	35% ^j	38%	34%	39%	37%	111%

^A Calculated based on average shares outstanding during the period.

⁸ Net investment income (loss) is affected by the timing of the declaration of dividends by any underlying mutual funds or exchange-traded funds (ETFs). Net investment income (loss) of any mutual funds or ETFs is not included in the Fund's net investment income (loss) ratio.

^c The amount shown reflects reclassifications related to book to tax differences that were made in the year shown.

D Total distributions per share do not sum due to rounding.

^E Total returns for periods of less than one year are not annualized.

F Total returns do not reflect charges attributable to your insurance company's separate account. Inclusion of these charges would reduce the total returns shown.

⁶ Total returns would have been lower if certain expenses had not been reduced during the applicable periods shown.

* Fees and expenses of any underlying mutual funds or exchange-traded funds (ETFs) are not included in the Fund's expense ratio. The Fund indirectly bears its proportionate share of these expenses. For additional expense information related to investments in Fidelity Central Funds, please refer to the "Investments in Fidelity Central Funds" note found in the Notes to Financial Statements section of the most recent Annual or Semi-Annual report.

Expense ratios reflect operating expenses of the class. Expenses before reductions do not reflect amounts reimbursed, waived, or reduced through arrangements with the investment adviser, brokerage services, or other offset arrangements, if applicable, and do not represent the amount paid by the class during periods when reimbursements, waivers or reductions occur.

^J Annualized.

K Amount does not include the portfolio activity of any underlying mutual funds or exchange-traded funds (ETFs).

VIP Contrafund[™] Portfolio Service Class 2

	Six months ended audited) June 30, 2023	Years ended December 31, 2022	2021		2020	2019	2018
Selected Per-Share Data							
Net asset value, beginning of period	\$ 36.54	\$ 52.51	\$ 46.7	3\$	36.10	\$ 31.31	\$ 37.05
Income from Investment Operations							
Net investment income (loss) ^{A,B}	.07	.11	(.08)	(.03)	.08	.14
Net realized and unrealized gain (loss)	 7.50	(13.87)			10.90	 8.89	 (2.44)
Total from investment operations	 7.57	(13.76)	12.3	8	10.87	 8.97	 (2.30)
Distributions from net investment income	-	(.11)	_0	,D	(.03)	(.07)	(.16)
Distributions from net realized gain	 (.38)	(2.09)	(6.60)	D	(.21)	 (4.11)	 (3.28)
Total distributions	 (.38)	(2.21)	(6.60)	(.24)	 (4.18)	 (3.44)
Net asset value, end of period	\$ 43.73	\$ 36.54	\$ 52.5	1\$	46.73	\$ 36.10	\$ 31.31
Total Return ^{F,G,H}	 20.85%	(26.49)%	27.519	%	30.23%	 31.27%	 (6.64)%
Ratios to Average Net Assets B,I,J							
Expenses before reductions	.85% ^к	.85%	.85	6	.86%	.86%	.87%
Expenses net of fee waivers, if any	.84% ^к	.85%	.85	6	.86%	.86%	.87%
Expenses net of all reductions	.84% ^ĸ	.85%	.85	6	.86%	.86%	.86%
Net investment income (loss)	.37% ^к	.25%	(.17)	6	(.08)%	.23%	.39%
Supplemental Data							
Net assets, end of period (000 omitted)	\$ 7,535,147	\$ 6,472,771	\$ 9,861,43	5\$	8,379,335	\$ 8,038,646	\$ 6,979,731
Portfolio turnover rate $^{\rm L}$	35% ^к	38%	349	6	39%	37%	111%

^A Calculated based on average shares outstanding during the period.

⁸ Net investment income (loss) is affected by the timing of the declaration of dividends by any underlying mutual funds or exchange-traded funds (ETFs). Net investment income (loss) of any mutual funds or ETFs is not included in the Fund's net investment income (loss) ratio.

^c Amount represents less than \$.005 per share.

^D The amount shown reflects reclassifications related to book to tax differences that were made in the year shown.

^E Total distributions per share do not sum due to rounding.

^F Total returns for periods of less than one year are not annualized.

6 Total returns do not reflect charges attributable to your insurance company's separate account. Inclusion of these charges would reduce the total returns shown.

^H Total returns would have been lower if certain expenses had not been reduced during the applicable periods shown.

Fees and expenses of any underlying mutual funds or exchange-traded funds (ETFs) are not included in the Fund's expense ratio. The Fund indirectly bears its proportionate share of these expenses. For additional expense information related to investments in Fidelity Central Funds, please refer to the "Investments in Fidelity Central Funds" note found in the Notes to Financial Statements section of the most recent Annual or Semi-Annual report.

Expense ratios reflect operating expenses of the class. Expenses before reductions do not reflect amounts reimbursed, waived, or reduced through arrangements with the investment adviser, brokerage services, or other offset arrangements, if applicable, and do not represent the amount paid by the class during periods when reimbursements, waivers or reductions occur.

^K Annualized.

¹ Amount does not include the portfolio activity of any underlying mutual funds or exchange-traded funds (ETFs).

VIP Contrafund[™] Portfolio Investor Class

	(U	Six months ended naudited) June 30, 2023		Years ended December 31, 2022	2021	2020		2019	2018
Selected Per-Share Data									
Net asset value, beginning of period	\$	37.56	\$_	<u> </u>	47.83	\$ 36.91	\$	31.93	\$ 37.74
Income from Investment Operations									
Net investment income (loss) A,B		.11		.18	_ (.04		.14	.20
Net realized and unrealized gain (loss)	_	7.72	_	(14.26)	12.78	 11.16		9.08	 (2.49)
Total from investment operations	_	7.83	_	(14.08)	12.78	 11.20	_	9.22	 (2.29)
Distributions from net investment income		-		(.19)	(.01) ^D	(.07)		(.14)	(.23)
Distributions from net realized gain	_	(.38)	_	(2.09)	(6.68) ^D	 (.21)	_	(4.11)	 (3.28)
Total distributions		(.38)	_	(2.28)	(6.69)	 (.28)	_	(4.24) ^E	 (3.52) ^E
Net asset value, end of period	\$	45.01	\$_	37.56 \$	53.92	\$ 47.83	\$	36.91	\$ 31.93
Total Return ^{F,G,H}		20.98%		(26.38)%	27.74%	 30.48%		31.49%	 (6.49)%
Ratios to Average Net Assets B,L									
Expenses before reductions		.68% ^к		.68%	.67%	.69%		.69%	.70%
Expenses net of fee waivers, if any		.67% ^к		.67%	.67%	.69%		.69%	.69%
Expenses net of all reductions		.67% ^к		.67%	.67%	.68%		.69%	.69%
Net investment income (loss)		.54% ^ĸ		.43%	.01%	.09%		.40%	.56%
Supplemental Data									
Net assets, end of period (000 omitted)	\$	2,119,813	\$	1,815,201 \$	2,622,106	\$ 2,101,100	\$	1,716,187	\$ 1,402,867
Portfolio turnover rate $^{\rm L}$		35% ^к		38%	34%	39%		37%	111%

^A Calculated based on average shares outstanding during the period.

⁸ Net investment income (loss) is affected by the timing of the declaration of dividends by any underlying mutual funds or exchange-traded funds (ETFs). Net investment income (loss) of any mutual funds or ETFs is not included in the Fund's net investment income (loss) ratio.

^c Amount represents less than \$.005 per share.

^D The amount shown reflects reclassifications related to book to tax differences that were made in the year shown.

^E Total distributions per share do not sum due to rounding.

^F Total returns for periods of less than one year are not annualized.

⁶ Total returns do not reflect charges attributable to your insurance company's separate account. Inclusion of these charges would reduce the total returns shown.

^H Total returns would have been lower if certain expenses had not been reduced during the applicable periods shown.

Fees and expenses of any underlying mutual funds or exchange-traded funds (ETFs) are not included in the Fund's expense ratio. The Fund indirectly bears its proportionate share of these expenses. For additional expense information related to investments in Fidelity Central Funds, please refer to the "Investments in Fidelity Central Funds" note found in the Notes to Financial Statements section of the most recent Annual or Semi-Annual report.

Expense ratios reflect operating expenses of the class. Expenses before reductions do not reflect amounts reimbursed, waived, or reduced through arrangements with the investment adviser, brokerage services, or other offset arrangements, if applicable, and do not represent the amount paid by the class during periods when reimbursements, waivers or reductions occur.

^K Annualized.

¹ Amount does not include the portfolio activity of any underlying mutual funds or exchange-traded funds (ETFs).

Notes to Financial Statements (Unaudited)

For the period ended June 30, 2023

1. Organization.

VIP Contrafund Portfolio (the Fund) is a fund of Variable Insurance Products Fund II (the Trust) and is authorized to issue an unlimited number of shares. The Trust is registered under the Investment Company Act of 1940, as amended (the 1940 Act), as an open-end management investment company organized as a Massachusetts business trust. Shares of the Fund may only be purchased by insurance companies for the purpose of funding variable annuity or variable life insurance contracts. The Fund offers the following classes of shares: Initial Class shares, Service Class shares, Service Class 2 shares and Investor Class shares. All classes have equal rights and voting privileges, except for matters affecting a single class.

2. Investments in Fidelity Central Funds.

Funds may invest in Fidelity Central Funds, which are open-end investment companies generally available only to other investment companies and accounts managed by the investment adviser and its affiliates. The Schedule of Investments lists any Fidelity Central Funds held as an investment as of period end, but does not include the underlying holdings of each Fidelity Central Fund. An investing fund indirectly bears its proportionate share of the expenses of the underlying Fidelity Central Funds.

Based on its investment objective, each Fidelity Central Fund may invest or participate in various investment vehicles or strategies that are similar to those of the investing fund. These strategies are consistent with the investment objectives of the investing fund and may involve certain economic risks which may cause a decline in value of each of the Fidelity Central Funds and thus a decline in the value of the investing fund.

Fidelity Central Fund	Investment Manager	Investment Objective	Investment Practices	Expense Ratio ^A
Fidelity Money Market Central Funds	Fidelity Management & Research Company	Each fund seeks to obtain a high level of	Short-term Investments	Less than .005%
	LLC (FMR)	current income consistent with the preservatio	n	
		of capital and liquidity.		

^A Expenses expressed as a percentage of average net assets and are as of each underlying Central Fund's most recent annual or semi-annual shareholder report.

A complete unaudited list of holdings for each Fidelity Central Fund is available upon request or at the Securities and Exchange Commission website at www.sec.gov. In addition, the financial statements of the Fidelity Central Funds which contain the significant accounting policies (including investment valuation policies) of those funds, and are not covered by the Report of Independent Registered Public Accounting Firm, are available on the Securities and Exchange Commission website or upon request.

3. Significant Accounting Policies.

The Fund is an investment company and applies the accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 *Financial Services - Investment Companies.* The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), which require management to make certain estimates and assumptions at the date of the financial statements. Actual results could differ from those estimates. Subsequent events, if any, through the date that the financial statements were issued have been evaluated in the preparation of the financial statements. The Fund's Schedule of Investments lists any underlying mutual funds or exchange-traded funds (ETFs) but does not include the underlying holdings of these funds. The following summarizes the significant accounting policies of the Fund:

Investment Valuation. Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.

The Fund categorizes the inputs to valuation techniques used to value its investments into a disclosure hierarchy consisting of three levels as shown below:

- Level 1 unadjusted quoted prices in active markets for identical investments
- Level 2 other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
- Level 3 unobservable inputs (including the Fund's own assumptions based on the best information available)

Valuation techniques used to value the Fund's investments by major category are as follows:

Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party

pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.

Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. Preferred securities are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.

Investments in open-end mutual funds, including the Fidelity Central Funds, are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. The aggregate value of investments by input level as of June 30, 2023 is included at the end of the Fund's Schedule of Investments.

Foreign Currency. Certain Funds may use foreign currency contracts to facilitate transactions in foreign-denominated securities. Gains and losses from these transactions may arise from changes in the value of the foreign currency or if the counterparties do not perform under the contracts' terms.

Foreign-denominated assets, including investment securities, and liabilities are translated into U.S. dollars at the exchange rates at period end. Purchases and sales of investment securities, income and dividends received, and expenses denominated in foreign currencies are translated into U.S. dollars at the exchange rate in effect on the transaction date.

The effects of exchange rate fluctuations on investments are included with the net realized and unrealized gain (loss) on investment securities. Other foreign currency transactions resulting in realized and unrealized gain (loss) are disclosed separately.

Investment Transactions and Income. For financial reporting purposes, the Fund's investment holdings and NAV include trades executed through the end of the last business day of the period. The NAV per share for processing shareholder transactions is calculated as of the close of business of the New York Stock Exchange (NYSE), normally 4:00 p.m. Eastern time and includes trades executed through the end of the prior business day. Gains and losses on securities sold are determined on the basis of identified cost and include proceeds received from litigation. Commissions paid to certain brokers with whom the investment adviser, or its affiliates, places trades on behalf of a fund include an amount in addition to trade execution, which may be rebated back to a fund. Any such rebates are included in net realized gain (loss) on investments in the Statement of Operations. Dividend income is recorded on the ex-dividend date, except for certain dividends from foreign securities where the ex-dividend date may have passed, which are recorded as soon as the Fund is informed of the ex-dividend date. Non-cash dividends include in dividend income, if any, are recorded at the fair market value of the securities received. Income and capital gain distributions from Fidelity Central Funds, if any, are recorded on the ex-dividend date, based upon receipt of tax filings or other correspondence relating to the underlying investment. These distributions are recorded as a reduction of cost of investments and/or as a realized gain. Interest income is accrued as earned and includes coupon interest and amortization of premium and accretion of discount on debt securities as applicable. Investment income is recorded in the Statement of Operations in dividends. Any receivables for withholding tax reclaims are included in the Statement of Assets and Liabilities in dividends receivable.

Class Allocations and Expenses. Investment income, realized and unrealized capital gains and losses, common expenses of a fund, and certain fund-level expense reductions, if any, are allocated daily on a pro-rata basis to each class based on the relative net assets of each class to the total net assets of a fund. Each class differs with respect to transfer agent and distribution and service plan fees incurred, as applicable. Certain expense reductions may also differ by class, if applicable. For the reporting period, the allocated portion of income and expenses to each class as a percent of its average net assets may vary due to the timing of recording these transactions in relation to fluctuating net assets of the classes. Expenses directly attributable to a fund are charged to that fund. Expenses attributable to more than one fund are allocated among the respective funds on the basis of relative net assets or other appropriate methods. Expenses included in the accompanying financial statements reflect the expenses of that fund and do not include any expenses associated with any underlying mutual funds or exchange-traded funds (ETFs). Although not included in a fund's expenses, a fund indirectly bears its proportionate share of these expenses through the net asset value of each underlying mutual fund or exchange-traded fund (ETF). Expense estimates are accrued in the period to which they relate and adjustments are made when actual amounts are known.

Deferred Trustee Compensation. Under a Deferred Compensation Plan (the Plan) for certain Funds, certain independent Trustees have elected to defer receipt of a portion of their annual compensation. Deferred amounts are invested in affiliated mutual funds, are marked-to-market and remain in a fund until distributed in accordance with the Plan. The investment of deferred amounts and the offsetting payable to the Trustees presented below are included in the accompanying Statement of Assets and Liabilities in other receivables and other payables and accrued expenses, as applicable.

VIP Contrafund Portfolio

\$769,022

Notes to Financial Statements (Unaudited) - continued

Income Tax Information and Distributions to Shareholders. Each year, the Fund intends to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code, including distributing substantially all of its taxable income and realized gains. As a result, no provision for U.S. Federal income taxes is required. The Fund files a U.S. federal tax return, in addition to state and local tax returns as required. The Fund's federal income tax returns are subject to examination by the Internal Revenue Service (IRS) for a period of three fiscal years after they are filed. State and local tax returns may be subject to examination for an additional fiscal year depending on the jurisdiction. Foreign taxes are provided for based on the Fund's understanding of the tax rules and rates that exist in the foreign markets in which it invests. The Fund is subject to a tax imposed on capital gains by certain countries in which it invests. An estimated deferred tax liability for net unrealized appreciation on the applicable securities is included in Other payables and accrued expenses on the Statement of Assets & Liabilities.

Distributions are declared and recorded on the ex-dividend date. Income and capital gain distributions are declared separately for each class. Income and capital gain distributions are determined in accordance with income tax regulations, which may differ from GAAP.

Capital accounts within the financial statements are adjusted for permanent book-tax differences. These adjustments have no impact on net assets or the results of operations. Capital accounts are not adjusted for temporary book-tax differences which will reverse in a subsequent period.

Book-tax differences are primarily due to foreign currency transactions, certain foreign taxes, passive foreign investment companies (PFIC), deferred Trustee compensation and losses deferred due to wash sales and excise tax regulations.

As of period end, the cost and unrealized appreciation (depreciation) in securities, and derivatives if applicable, for federal income tax purposes were as follows:

Gross unrealized appreciation	\$9,477,893,568
Gross unrealized depreciation	<u>(133,492,034)</u>
Net unrealized appreciation (depreciation)	<u>\$9,344,401,534</u>
Tax cost	<u>\$10,144,437,215</u>

Restricted Securities (including Private Placements). Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities held at period end is included at the end of the Schedule of Investments, if applicable.

Consolidated Subsidiary. The Funds included in the table below hold certain investments through a wholly-owned subsidiary ("Subsidiary"), which may be subject to federal and state taxes upon disposition.

As of period end, investments in Subsidiaries were as follows:

	\$ Amount	% of Net Assets
VIP Contrafund Portfolio	7,934,883	.04

The financial statements have been consolidated to include the Subsidiary accounts where applicable. Accordingly, all inter-company transactions and balances have been eliminated.

At period end, any estimated tax liability for these investments is presented as "Deferred taxes" in the Statement of Assets and Liabilities and included in "Change in net unrealized appreciation (depreciation) on investment securities" in the Statement of Operations. The tax liability incurred may differ materially depending on conditions when these investments are disposed. Any cash held by a Subsidiary is restricted as to its use and is presented as "Restricted cash" in the Statement of Assets and Liabilities, if applicable.

4. Purchases and Sales of Investments.

Purchases and sales of securities, other than short-term securities and in-kind transactions, as applicable, are noted in the table below.

	Purchases (\$)	Sales (\$)
VIP Contrafund Portfolio	3,033,847,724	3,696,537,558

5. Fees and Other Transactions with Affiliates.

Management Fee. Fidelity Management & Research Company LLC (the investment adviser) and its affiliates provide the Fund with investment management related services for which the Fund pays a monthly management fee. The management fee is the sum of an individual fund fee rate that is based on an annual rate of .30% of the Fund's average net assets and an annualized group fee rate that averaged .23% during the period. The group fee rate is based upon the monthly average net assets of a group of registered investment companies with which the investment adviser has management contracts. The group fee rate decreases as assets under management increase and increases as assets under management decrease. For the reporting

period, the total annualized management fee rate was .52% of the Fund's average net assets.

Distribution and Service Plan Fees. In accordance with Rule 12b-1 of the 1940 Act, the Fund has adopted separate 12b-1 Plans for each Service Class of shares. Each Service Class pays Fidelity Distributors Company LLC (FDC), an affiliate of the investment adviser, a service fee. For the period, the service fee is based on an annual rate of .10% of Service Class' average net assets and .25% of Service Class 2's average net assets.

For the period, total fees, all of which were re-allowed to insurance companies for the distribution of shares and providing shareholder support services, were as follows:

Service Class Service Class 2	\$713,712 <u>8,725,222</u> <u>\$9,438,934</u>
----------------------------------	---

Transfer Agent Fees. Fidelity Investments Institutional Operations Company LLC (FIIOC), an affiliate of the investment adviser, is the Fund's transfer, dividend disbursing, and shareholder servicing agent. FIIOC receives an asset-based fee with respect to each class. Each class pays a fee for transfer agent services, typesetting and printing and mailing of shareholder reports, excluding mailing of proxy statements. For the period, transfer agent fees for each class were as follows:

	Amount	% of Class-Level Average Net Assets [▲]
Initial Class	\$2,429,948	.06
Service Class	449,638	.06
Service Class 2	2,198,756	.06
Investor Class	<u>1,344,191</u>	.14
	<u>\$6,422,533</u>	

A Annualized

Accounting Fees. Fidelity Service Company, Inc. (FSC), an affiliate of the investment adviser, maintains the Fund's accounting records. The accounting fee is based on the level of average net assets for each month. For the period, the fees were equivalent to the following annualized rates:

VIP Contrafund Portfolio

Brokerage Commissions. A portion of portfolio transactions were placed with brokerage firms which are affiliates of the investment adviser. Brokerage commissions are included in net realized gain (loss) and change in net unrealized appreciation (depreciation) in the Statement of Operations. The commissions paid to these affiliated firms were as follows:

VIP Contrafund Portfolio

Interfund Trades. Funds may purchase from or sell securities to other Fidelity Funds under procedures adopted by the Board. The procedures have been designed to ensure these interfund trades are executed in accordance with Rule 17a-7 of the 1940 Act. Any interfund trades are included within the respective purchases and sales amounts shown in the Purchases and Sales of Investments note. Interfund trades during the period are noted in the table below.

	Purchases (\$)	Sales (\$)	Realized Gain (Loss) (\$)
VIP Contrafund Portfolio	101,236,861	181,583,748	18,040,609

6. Committed Line of Credit.

Certain Funds participate with other funds managed by the investment adviser or an affiliate in a \$4.25 billion credit facility (the "line of credit") to be utilized for temporary or emergency purposes to fund shareholder redemptions or for other short-term liquidity purposes. The participating funds have agreed to pay commitment fees on their pro-rata portion of the line of credit, which are reflected in Miscellaneous expenses on the Statement of Operations, and are listed below. During the period, there were no borrowings on this line of credit.

VIP Contrafund Portfolio

7. Security Lending.

Funds lend portfolio securities from time to time in order to earn additional income. Lending agents are used, including National Financial Services (NFS), an affiliate of the investment adviser. Pursuant to a securities lending agreement, NFS will receive a fee, which is capped at 9.9% of a fund's daily lending revenue, for its services as lending agent. A fund may lend securities to certain qualified borrowers, including NFS. On the settlement date of the loan, a fund receives collateral (in the form of U.S. Treasury obligations, letters of credit and/or cash) against the loaned securities and maintains collateral in an amount not less than 100% of the market value of the loaned securities during the period of the loan. The market value of the loaned securities

01

% of Average Net Assets

Amount

\$36,161

Amount \$17,159

Notes to Financial Statements (Unaudited) - continued

is determined at the close of business of a fund and any additional required collateral is delivered to a fund on the next business day. A fund or borrower may terminate the loan at any time, and if the borrower defaults on its obligation to return the securities loaned because of insolvency or other reasons, a fund may apply collateral received from the borrower against the obligation. A fund may experience delays and costs in recovering the securities loaned. Any cash collateral received is invested in the Fidelity Securities Lending Cash Central Fund. Any loaned securities are identified as such in the Schedule of Investments, and the value of loaned securities and cash collateral at period end, as applicable, are presented in the Statement of Assets and Liabilities. Security lending income represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities. Security lending income is presented in the Statement of Operations as a component of income from Fidelity Central Funds. Affiliated security lending activity, if any, was as follows:

	Total Security Lending Fees Paid to NFS	Security Lending Income From Securities Loaned to NFS	Value of Securities Loaned to NFS at Period End
VIP Contrafund Portfolio	\$3,040	Ş-	Ş-

8. Expense Reductions.

During the period the investment adviser or an affiliate reimbursed and/or waived a portion of fund-level operating expenses in the amount of \$403,743.

9. Distributions to Shareholders.

Distributions to shareholders of each class were as follows:

	Six months ended	Year ended
	June 30, 2023	December 31, 2022
VIP Contrafund Portfolio		
Distributions to shareholders		
Initial Class	\$71,948,292	\$427,834,614
Service Class	13,326,343	78,033,095
Service Class 2	67,015,734	381,182,952
Investor Class	<u>17,938,323</u>	<u>106,683,299</u>
Total	<u>\$170,228,692</u>	<u>\$993,733,960</u>

10. Share Transactions.

Transactions for each class of shares were as follows and may contain in-kind transactions:

	Shares Six months ended	Shares Year ended	Dollars Six months ended	Dollars Year ended
	June 30, 2023	December 31, 2022	June 30, 2023	December 31, 2022
VIP Contrafund Portfolio Initial Class				
Shares sold	1,911,232	8,378,273	\$78,020,279	\$363,798,629
Reinvestment of distributions	1,792,434	10,481,286	71,948,292	427,834,614
Shares redeemed Net increase (decrease)	<u>(13,748,966)</u> (10,045,300)	<u>(18,832,607)</u> <u>26,952</u>	<u>(567,098,727)</u> \$(417,130,156)	<u>(811,370,836)</u> \$(19,737,593)
	(10,045,500)	<u>20,732</u>	<u>\$(417,130,150)</u>	<u>3(17,737,373)</u>
Service Class Shares sold	698,775	1,591,965	\$28,370,800	\$69,369,182
Reinvestment of distributions	334,245	1,919,691	13,326,343	78,033,095
Shares redeemed Net increase (decrease)	<u>(2,124,293)</u> (1,091,273)	<u>(5,310,438)</u> (1,798,782)	<u>(87,532,086)</u> \$(45,834,943)	<u>(225,918,720)</u> \$(78,516,443)
	(1,071,273)	<u>(1,770,702)</u>	<u>, (17, 100, 17)</u>	<u>, 10, 510, 443/</u>
Service Class 2	0 201 201	11 040 040	Č000 Z07 000	Ċ450.004.404
Shares sold Reinvestment of distributions	8,381,321 1,732,120	11,049,242 9,646,091	\$330,786,229 67,015,734	\$459,094,624 381,182,952
Shares redeemed	(14,962,727)	(31,323,576)	(594,986,110)	(1,277,383,639)
Net increase (decrease)	(4,849,286)	(10,628,243)	\$(197,184,147)	\$(437,106,063)
Investor Class				
Shares sold	548,710	1,027,613	\$22,821,218	\$45,322,045
Reinvestment of distributions	450,712	2,633,470	17,938,323	106,683,299
Shares redeemed	<u>(2,227,279)</u>	(3,966,429)	(89,704,856)	(168,358,809)
Net increase (decrease)	<u>(1,227,857)</u>	<u>(305,346)</u>	<u>\$(48,945,315)</u>	<u>\$(16,353,465)</u>

11. Other.

A fund's organizational documents provide former and current trustees and officers with a limited indemnification against liabilities arising in connection with the performance of their duties to

the fund. In the normal course of business, a fund may also enter into contracts that provide general indemnifications. A fund's maximum exposure under these arrangements is unknown as this would be dependent on future claims that may be made against a fund. The risk of material loss from such claims is considered remote.

At the end of the period, the investment adviser or its affiliates were owners of record of more than 10% and certain otherwise unaffiliated shareholders each were owners of record of more than 10% of the outstanding shares as follows:

Fund	Affiliated %	Number ofUnaffiliated Shareholders	Unaffiliated Shareholders %
VIP Contrafund Portfolio	16%	2	23%

12. Risk and Uncertainties.

Many factors affect a fund's performance. Developments that disrupt global economies and financial markets, such as pandemics, epidemics, outbreaks of infectious diseases, war, terrorism, and environmental disasters, may significantly affect a fund's investment performance. The effects of these developments to a fund will be impacted by the types of securities in which a fund invests, the financial condition, industry, economic sector, and geographic location of an issuer, and a fund's level of investment in the securities of that issuer. Significant concentrations in security types, issuers, industries, sectors, and geographic locations may magnify the factors that affect a fund's performance.

Shareholder Expense Example

As a shareholder, you incur two types of costs: (1) transaction costs, which may include sales charges (loads) on purchase payments or redemption proceeds, as applicable and (2) ongoing costs, which generally include management fees, distribution and/or service (12b-1) fees and other Fund expenses. This Example is intended to help you understand your ongoing costs (in dollars) of investing in a fund and to compare these costs with the ongoing costs of investing in other mutual funds.

The Example is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period (January 1, 2023 to June 30, 2023).

Actual Expenses

The first line of the accompanying table provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000.00 (for example, an \$8,600 account value divided by \$1,000.00 = 8.6), then multiply the result by the number in the first line for a class/Fund under the heading entitled "Expenses Paid During Period" to estimate the expenses you paid on your account during this period. If any fund is a shareholder of any underlying mutual funds or exchange-traded funds (ETFs) (the Underlying Funds), such fund indirectly bears its proportional share of the expenses of the Underlying Funds in addition to the direct expenses incurred presented in the table. These fees and expenses are not included in the annualized expense ratio used to calculate the expense estimate in the table below. The estimate of expenses does not include any fees or other expenses of any variable annuity or variable life insurance product. If they were, the estimate of expenses you paid during the period would be higher, and your ending account value would be lower.

Hypothetical Example for Comparison Purposes

The second line of the accompanying table provides information about hypothetical account values and hypothetical expenses based on the actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds. If any fund is a shareholder of any Underlying Funds, such fund indirectly bears its proportional share of the expenses of the Underlying Funds in addition to the direct expenses as presented in the table. These fees and expenses are not included in the annualized expense ratio used to calculate the expense estimate in the table below. The estimate of expenses does not include any fees or other expenses of any variable annuity or variable life insurance product. If they were, the estimate of expenses you paid during the period would be higher, and your ending account value would be lower.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transaction costs. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

	Annualized Expense Ratio-A	Beginning Account Value January 1, 2023	Ending Account Value June 30, 2023	Expenses Paid During Period ^{. (} January 1, 2023 to June 30, 2023
VIP Contrafund™ Portfolio Initial Class	.59%			
Actual		\$ 1,000	\$ 1,210,10	\$ 3.23
			\$ 1,021.87	\$ 3.23 \$ 2.96
Hypothetical [®] Service Class	.69%	\$ 1,000	\$ 1,021.07	\$ 2.70
	.07%	Ċ 1 000	ć 1 000 40	ć 0.70
Actual		\$ 1,000	\$ 1,209.40	\$ 3.78
Hypothetical [®]	• • • •	\$ 1,000	\$ 1,021.37	\$ 3.46
Service Class 2	.84%			
Actual		\$ 1,000	\$ 1,208.50	\$ 4.60
Hypothetical [®]		\$ 1,000	\$ 1,020.63	\$ 4.21
Investor Class	.67%			
Actual		\$ 1,000	\$ 1,209.80	\$ 3.67
Hypothetical ^B		\$ 1,000	\$ 1,021.47	\$ 3.36

A Annualized expense ratio reflects expenses net of applicable fee waivers.

B 5% return per year before expenses

C Expenses are equal to the annualized expense ratio, multiplied by the average account value over the period, multiplied by 181/365 (to reflect the one-half year period). The fees and expenses of any Underlying Funds are not included in each annualized expense ratio.

Board Approval of Investment Advisory Contracts

Board Approval of Investment Advisory Contracts

VIP Contrafund Portfolio

At its May 2023 meeting, the Board of Trustees, including the Independent Trustees (together, the Board), voted to continue the management contract with Fidelity Management & Research Company LLC (FMR), and the sub-advisory agreements and sub-subadvisory agreements, in each case, where applicable (together, the Advisory Contracts) for the fund for two months from June 1, 2023 through July 31, 2023. The Board determined that it will consider the annual renewal of the fund's Advisory Contracts for a full one year period in July 2023, following its review of additional materials provided by FMR.

The Board considered that the approval of the fund's Advisory Contracts will not result in any changes in (i) the investment process or strategies employed in the management of the fund's assets; (ii) the fees and expenses paid by shareholders; (iii) the nature, extent or quality of services provided under the fund's Advisory Contracts; or (iv) the day-to-day management of the fund or the persons primarily responsible for such management. The Board also considered that since its last approval of the fund's Advisory Contracts, FMR had provided additional information on the fund in support of the annual contract renewal process, including competitive analyses on total expenses and management fees and in-depth reviews of fund performance and fund profitability information. The Board concluded that the fund's Advisory Contracts are fair and reasonable, and that the fund's Advisory Contracts should be renewed, without modification, through July 31, 2023, with the understanding that the Board will consider the annual renewal for a full one year period in July 2023.

In connection with its consideration of future renewals of the fund's Advisory Contracts, the Board will consider: (i) the nature, extent and quality of services provided to the fund, including shareholder and administrative services and investment performance; (ii) the competitiveness of the management fee and total expenses for the fund; (iii) the costs of the services and profitability, including the revenues earned and the expenses incurred in conducting the business of developing, marketing, distributing, managing, administering, and servicing the fund and its shareholders, to the extent applicable; and (iv) whether there have been economies of scale in respect of the Fidelity funds, whether the Fidelity funds (including the fund) have appropriately benefited from any such economies of scale, and whether there is the potential for realization of any further economies.

Based on its evaluation of all of the conclusions noted above, and after considering all factors it believed relevant, the Board ultimately concluded that the fund's management fee structure is fair and reasonable, and that the continuation of the fund's Advisory Contracts should be approved for two months from June 1, 2023 through July 31, 2023.

Liquidity Risk Management Program

The Securities and Exchange Commission adopted Rule 22e-4 under the Investment Company Act of 1940 (the Liquidity Rule) to promote effective liquidity risk management throughout the open-end investment company industry, thereby reducing the risk that funds will be unable to meet their redemption obligations and mitigating dilution of the interests of fund shareholders.

The Fund has adopted and implemented a liquidity risk management program (the Program) reasonably designed to assess and manage the Fund's liquidity risk and to comply with the requirements of the Liquidity Rule. The Fund's Board of Trustees (the Board) has designated the Fund's investment adviser as administrator of the Program. The Fidelity advisers have established a Liquidity Risk Management Committee (the LRM Committee) to manage the Program for each of the Fidelity Funds. The LRM Committee monitors the adequacy and effectiveness of implementation of the Program and on a periodic basis assesses each Fund's liquidity risk based on a variety of factors including (1) the Fund's investment strategy, (2) portfolio liquidity and cash flow projections during normal and reasonably foreseeable stressed conditions, (3) shareholder redemptions, (4) borrowings and other funding sources and (5) certain factors specific to ETFs including the effect of the Fund's prices and spreads, market participants, and basket compositions on the overall liquidity of the Fund's portfolio, as applicable.

In accordance with the Program, each of the Fund's portfolio investments is classified into one of four defined liquidity categories based on a determination of a reasonable expectation for how long it would take to convert the investment to cash (or sell or dispose of the investment) without significantly changing its market value.

- Highly liquid investments cash or convertible to cash within three business days or less
- Moderately liquid investments convertible to cash in three to seven calendar days
- Less liquid investments can be sold or disposed of, but not settled, within seven calendar days
- Illiquid investments cannot be sold or disposed of within seven calendar days

Liquidity classification determinations take into account a variety of factors including various market, trading and investment-specific considerations, as well as market depth, and generally utilize analysis from a third-party liquidity metrics service.

The Liquidity Rule places a 15% limit on a fund's illiquid investments and requires funds that do not primarily hold assets that are highly liquid investments to determine and maintain a minimum percentage of the fund's net assets to be invested in highly liquid investments (highly liquid investment minimum or HLIM). The Program includes provisions reasonably designed to comply with the 15% limit on illiquid investments and for determining, periodically reviewing and complying with the HLIM requirement as applicable.

At a recent meeting of the Fund's Board of Trustees, the LRM Committee provided a written report to the Board pertaining to the operation, adequacy, and effectiveness of the Program for the period December 1, 2021 through November 30, 2022. The report concluded that the Program is operating effectively and is reasonably designed to assess and manage the Fund's liquidity risk.

